var title_f21_33_22032="Disseminated granuloma annulare - annular lesions";
var content_f21_33_22032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71308&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disseminated granuloma annulare",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 42 year-old patient with disseminated granuloma annulare presented with 200 annular lesions ranging from 5-25 mm in diameter on the arms, legs, and trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22032=[""].join("\n");
var outline_f21_33_22032=null;
var title_f21_33_22033="Transient neonatal pustular melanosis 1";
var content_f21_33_22033=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Transient neonatal pustular melanosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pustules, collarettes of scales, and hyperpigmented macules in a neonate with transient pustular melanosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22033=[""].join("\n");
var outline_f21_33_22033=null;
var title_f21_33_22034="Serous cystadenoma EUS";
var content_f21_33_22034=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pancreatic serous cystadenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 417px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Appearance of a pancreatic serous cystadenoma on endoscopic ultrasound.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Levy, MD and Maurits J Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22034=[""].join("\n");
var outline_f21_33_22034=null;
var title_f21_33_22035="Infection timeline SOT";
var content_f21_33_22035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 640px\">",
"   <div class=\"ttl\">",
"    The timeline of infections following solid organ transplantation",
"    <sup>",
"     [1-3]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 620px; height: 512px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Common patterns of opportunistic infection are observed following solid organ transplantation based on epidemiologic exposures and the \"net state of immunosuppression.\" The timeline is altered based on the immunosuppressive regimen and prophylactic medications. The dynamic assessment of infectious risk represents assays that will measure an individual's risk for infection due to specific pathogens or in general.",
"    <div class=\"footnotes\">",
"     CMV: cytomegalovirus; EBV: Epstein-Barr virus; HSV: herpes simplex virus; MRSA: methicillin-resistant Staphylococcus aureus; PML: progressive multifocal leukoencephalopathy; PTLD: posttransplant lymphoproliferative disorder; SARS: severe acute respiratory syndrome; VRE: vancomycin-resistant enterococcus; VZV: varicella zoster virus.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from:",
"     <br>",
"      <ol>",
"       <li>",
"        Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.",
"       </li>",
"       <li>",
"        Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection in the renal transplant recipient. Am J Med 1981; 70:405.",
"       </li>",
"       <li>",
"        Fishman JA, Rubin RH. Infection in organ-transplant recipients [see comments]. N Engl J Med 1998; 338:1741.",
"       </li>",
"      </ol>",
"      <br>",
"       From: Fishman JA, and the AST Infectious Diseases Community of Practice. Introduction: Infection in solid organ transplant recipients. Am J Transplant 2009; 9 (Suppl 4):S3. Copyright &copy; 2009 American Society of Transplantation and the American Society of Transplant Surgeons. Reproduced with permission of John Wiley &amp; Sons, Inc.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22035=[""].join("\n");
var outline_f21_33_22035=null;
var title_f21_33_22036="Pathologic fracture of a distal femur osteosarcoma";
var content_f21_33_22036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86777&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Osteosarcoma of the distal femur presenting as a pathologic fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 511px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Muchantef K, Pollock AN. Osteosarcoma of the lower extremity presenting as a pathologic fracture. Pediatr Emerg Care 2012; 28:936. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22036=[""].join("\n");
var outline_f21_33_22036=null;
var title_f21_33_22037="Arformoterol: Patient drug information";
var content_f21_33_22037=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Arformoterol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/50/30500?source=see_link\">",
"     see \"Arformoterol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F4010583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Brovana&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10016928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700378",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In patients with asthma, long-acting puffers (inhalers) raised asthma-related deaths. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to open the airways in lung diseases where spasm may cause breathing problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701542",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to arformoterol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having a breathing attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3378219",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are",
"       <b>",
"        not",
"       </b>",
"       using other asthma drugs. This drug must be used with a long-term asthma-control drug like a breathed in steroid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696945",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug to treat an asthma attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697883",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698249",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to get the breathing attack under control.",
"       <b>",
"        Get help right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor right away if your normal dose does not work as well or if you need to use your inhaler more often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to take this drug as you have been told by your doctor. Do not use more than you were told to use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694893",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For breathing in only as a liquid (solution) by a special machine (nebulizer) into the lungs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug more than 2 times in a day. Space doses by about 12 hours.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may store unopened containers at room temperature or in a refrigerator. Do not freeze. If stored at room temperature, throw away any unused containers after 6 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use right after opening.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use if solution changes color.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11982 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22037=[""].join("\n");
var outline_f21_33_22037=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4010583\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016928\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016930\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016929\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016934\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016935\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016937\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016932\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016933\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016938\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016939\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/50/30500?source=related_link\">",
"      Arformoterol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_33_22038="ECG tutorial: Intraventricular block";
var content_f21_33_22038=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   ECG tutorial: Intraventricular block",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22038/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22038/contributors\">",
"     Jordan M Prutkin, MD, MHS, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22038/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22038/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22038/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22038/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/33/22038/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H438225084\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bundle branch and fascicular blocks are frequently seen in those with and without cardiac disease. These patterns are defined by variations in QRS duration and voltage compared to normal. By convention, deflections on the ECG that are greater than 0.5 mV (ie, greater than 5 mm with standard calibration) are referred to in capital letters; smaller deflections are noted in lower case. Thus, a qRs pattern means that the q and s waves are small and the R wave is large.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     LEFT ANTERIOR FASCICULAR BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;A left anterior fascicular block, or hemiblock, is characterized by a pathologic left axis in the frontal limb leads, defined as an axis &gt;-45&ordm; or &gt;-60&ordm;, depending upon the author, up to -90&ordm;. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16886?source=see_link\">",
"     \"Left anterior fascicular block\"",
"    </a>",
"    .) This may be the result of conduction system disease in the anterior fascicle of the left bundle, or may occur when there is disease or fibrosis surrounding the left anterior fascicle (eg, with a myocardial infarction).",
"   </p>",
"   <p>",
"    The QRS measures &lt;0.12 seconds in duration. The QRS complexes in lead I are upright (",
"    <a class=\"graphic graphic_waveform graphicRef78636 \" href=\"UTD.htm?10/10/10402\">",
"     waveform 1",
"    </a>",
"    ); in the inferior leads II, III, and aVF they are negative (small R wave, deep S wave). There is a small q wave and tall R wave in lead aVL, and the time to the peak of the R wave in aVL is &ge;0.045 seconds. There is often a tall R wave in aVR and poor R wave progression in leads V1-V3.",
"   </p>",
"   <p>",
"    An inferior wall myocardial infarction also has a left axis as the result of a large Q wave in the inferior leads. This is due to fibrotic tissue rather than conduction system disease. If there is a QR complex due to infarction, the pattern has been called a peri-infarction block. Therefore, a left anterior fascicular block cannot be diagnosed in the presence of an inferior wall myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LEFT POSTERIOR FASCICULAR BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;A left posterior fascicular block, or hemiblock, occurs when there is conduction system disease involving the posterior fascicle of the left bundle branch. It is defined as a pathologic right axis, &gt;+90&ordm; (some authors use an even more rightward axis of 120&ordm;) up to 180&ordm;. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16420?source=see_link\">",
"     \"Left posterior fascicular block\"",
"    </a>",
"    .) The QRS complex is &lt;0.12 seconds. There are small R and deep S waves in leads I and aVL, and small Q and tall R waves in leads III and aVF (",
"    <a class=\"graphic graphic_waveform graphicRef51923 \" href=\"UTD.htm?31/60/32705\">",
"     waveform 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, there are other causes of a right axis that need to be considered and excluded before a left posterior fascicular block can be diagnosed, ie, a left posterior fascicular block is a diagnosis of exclusion. Other causes for a right axis include a lateral wall myocardial infarction (peri-infarction block), where there is a QR in leads I and aVL; right ventricular hypertrophy, in which case there is a tall R wave in lead V1; R-L arm lead switch, with a negative P wave, QRS complex, and T wave in leads I and aVL; dextrocardia, which resembles R-L arm lead switch and also has reverse R wave progression across the precordium; and Wolff-Parkinson-White with a pseudo lateral wall infarction pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RIGHT BUNDLE BRANCH BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;A right bundle branch block (RBBB) may be incomplete or complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Incomplete RBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;An incomplete RBBB is present when there is a slowing of or delayed conduction through the right bundle branch. It may also be seen with delayed activation of the right ventricle within the right ventricular myocardium. Although this is often termed an incomplete RBBB, it is actually an intraventricular conduction delay of the right ventricle as the bundles exhibit all or none conduction rather than incomplete conduction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9283?source=see_link\">",
"     \"ECG tutorial: Physiology of the conduction system\"",
"    </a>",
"    .) Activation of the septum and left ventricular myocardium is unaffected; thus, the initial part of the QRS complex is normal (eg, septal Q waves followed by a R wave). However, the delay in right ventricular myocardial activation causes it to occur after left ventricular activation rather than simultaneously, thereby altering the terminal portion of the QRS complex.",
"   </p>",
"   <p>",
"    The delayed right ventricular forces are directed from left to right, leading to a tall secondary R wave (R') in the rightward directed leads, and a deep terminal S wave in the leftward leads (",
"    <a class=\"graphic graphic_waveform graphicRef51809 \" href=\"UTD.htm?17/3/17460\">",
"     waveform 3",
"    </a>",
"    ). Thus, there is a rsR' in leads aVR and V1-V2, and a qRs morphology in leads I, aVL, and V5-6. However, the QRS complex width is only slightly prolonged, between 0.10 and 0.12 seconds, since there is only a minor delay in right ventricular activation that still occurs via the right bundle branch; hence, this is considered an intraventricular conduction delay.",
"   </p>",
"   <p>",
"    Incomplete RBBB may be erroneously seen if the V1 ECG lead is placed higher than the fourth intercostal space or more right than the parasternal area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Complete RBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete right bundle branch block is the result of a total block of impulse conduction along the right bundle branch, leading to delayed and abnormal activation of the right ventricular myocardium occurring from the left ventricular myocardium. The left bundle branch is not affected; thus, activation of the septum and left ventricular myocardium is normal, occurring first from left to right (septal depolarization) and then from right to left (ventricular depolarization). This is then followed by right ventricular activation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=see_link\">",
"     \"Right bundle branch block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9283?source=see_link\">",
"     \"ECG tutorial: Physiology of the conduction system\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The overall appearance of the QRS is an RsR&rsquo; complex in leads V1-2, commonly called a &ldquo;rabbit-ear&rdquo; pattern, and a deep, broad S wave in leads I, aVL, and V5-6. The width of the QRS complex is &gt;0.12 sec. The RBBB also results in an abnormality of ventricular repolarization of the right ventricular myocardium. Thus, there are often secondary ST segment and T wave changes present in the right precordial leads V1-V3, including ST depression and T wave inversions.",
"   </p>",
"   <p>",
"    The electrocardiogram (ECG) in RBBB can be best understood in terms of an early anterior vector, a mid-temporal and usually posterior vector, and a delayed terminal rightward vector (",
"    <a class=\"graphic graphic_movie graphicRef56402 \" href=\"UTD.htm?26/3/26677\">",
"     movie 1",
"    </a>",
"    ). The following are common observations (",
"    <a class=\"graphic graphic_waveform graphicRef64393 \" href=\"UTD.htm?42/12/43210\">",
"     waveform 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early anterior and rightward vector &mdash; Initial septal activation depends on fibers of the left bundle, as depolarization proceeds from left to right. The initial 30 msec of activation is not quite normal in RBBB, since some normally opposing rightward forces are not present. Nevertheless, the electrocardiographic appearance is essentially normal in that the anterior and rightward vector results in a q wave in leads I, aVL, and V6; and an r wave in leads V1, V2, and aVR (",
"      <a class=\"graphic graphic_waveform graphicRef65619 \" href=\"UTD.htm?7/46/7909\">",
"       waveform 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Mid-temporal leftward and usually posterior vector &mdash; The initial rightward vector of septal activation is followed by a leftward and posterior vector induced by subsequent left ventricular activation. The wave front completes depolarization of the left ventricle between 40 and 60 msec, resulting in R waves in I, aVL, and V6 as well as an s (or S) in V1 and V2. This appearance is usually similar to that in normal subjects.",
"     </li>",
"     <li>",
"      Delayed terminal rightward vector &mdash; The asynchronous depolarization caused by RBBB is primarily manifested in the later portion of the QRS complex, at 80 msec and beyond. Since the abnormal and delayed right ventricular activation occurs from left to right and goes through the ventricular myocardium and not the His-Purkinje system, the forces generated by right septal and right ventricular free wall activation predominate, resulting in a terminal rightward and anterior positivity. This also results in S waves in the leftward directed leads (I, aVL, and V6), and a second positive deflection is usually large (R'), in the anterior-posterior leads (V1 and V2).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As left ventricular activation is normal, abnormalities of the left ventricle can be still recognized, such as acute and chronic myocardial ischemia or infarction, left ventricular hypertrophy, and pericarditis. The right ventricular activation sequence is abnormal, however, and abnormalities of the right ventricular myocardium cannot be recognized (ie, right ventricular hypertrophy). An RBBB does not lead to axis deviation.",
"   </p>",
"   <p>",
"    Some patients have an atypical pattern with loss of the S wave in V1 due to anterior displacement of the usually posterior mid-temporal forces, resulting in an rsR', qR, or M-shaped QRS pattern in V1. There are three mechanisms that can account for this pattern: normal variant; a gain of mid-temporal anterior forces due to right ventricular enlargement or concurrent left anterior fascicular block; and a loss of posterior forces due to a posterior wall myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LEFT BUNDLE BRANCH BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left bundle branch block (LBBB) may be either incomplete or complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Incomplete LBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;An incomplete LBBB occurs when there is a slowing or delay of conduction through the left bundle, or diffusely through the Purkinje system and the ventricular myocardium. This causes a widening of the QRS complex to 0.10 to 0.12 seconds and loss of the septal q wave in leads I and V5-6. They will usually have a pattern resembling left ventricular hypertrophy and a time to the peak of the R wave in leads V4-6 is &gt;.06 seconds. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9283?source=see_link\">",
"     \"ECG tutorial: Physiology of the conduction system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Complete LBBB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete LBBB develops as a result of conduction delay or block within the left bundle branch, leading to delayed and abnormal activation of the left ventricular myocardium occurring from the right bundle branch and right ventricular myocardium. Left ventricular activation originates from the right bundle branch in a right to left direction, in contrast to the normal situation in which the first part of the left ventricular myocardium to be activated is the septum via a small septal branch of the left bundle, with subsequent impulse spread in a left to right direction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=see_link\">",
"     \"Left bundle branch block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9283?source=see_link\">",
"     \"ECG tutorial: Physiology of the conduction system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In common or typical complete LBBB, the conduction sequence is to the left and asynchronous activation of the two ventricles with delayed and slowed left ventricular activation increases the QRS duration.",
"   </p>",
"   <p>",
"    The following changes are seen on the ECG (",
"    <a class=\"graphic graphic_waveform graphicRef52836 \" href=\"UTD.htm?11/51/12085\">",
"     waveform 6",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The QRS interval is prolonged &gt;0.12 seconds since left ventricular activation is abnormal, delayed, and slowed due to conduction of the impulse through the ventricular myocardium rather than the His-Purkinje system.",
"     </li>",
"     <li>",
"      There are no septal Q waves in leads I and V5-V6; instead there is a tall monophasic broadened and abnormal R wave in these leads. Occasionally, a small q wave may be seen in aVL.",
"     </li>",
"     <li>",
"      The time to the peak of the R wave is &gt;0.06 seconds in leads V5-6.",
"     </li>",
"     <li>",
"      There is a QS complex that is abnormal and widened in leads V1-V2, though small R wave may be seen (rS complex).",
"     </li>",
"     <li>",
"      There are no left-to-right forces and hence there cannot be terminal S waves in leads I or V6.",
"     </li>",
"     <li>",
"      The QRS axis may be normal, but is frequently leftward. Occasionally, it may be superior or rightward. &nbsp;",
"     </li>",
"     <li>",
"      ST and T wave abnormalities may be present, including T wave inversions and ST segment depression, in the opposite direction from the QRS complex. These changes of myocardial repolarization are secondary to the abnormal ventricular activation. Positive concordance, where the QRS and T waves are both upright, may be seen as normal. Negative concordance, with both a negative QRS and T wave, is abnormal and would be concerning for",
"      <span class=\"nowrap\">",
"       ischemia/infarction.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9317?source=see_link&amp;anchor=H466175#H466175\">",
"       \"ECG tutorial: Myocardial infarction\", section on 'ST changes in the setting of conduction abnormalities'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It is not possible to diagnose other left ventricular abnormalities in the presence of an LBBB due to the abnormal conduction through the left ventricle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The electrocardiographic pattern in LBBB can be best understood in terms of three vectors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early and usually leftward vector &mdash; The normal sequence of activation at 10 msec (0.10 sec) is anterior and to the right (ie, representing septal activation), resulting in small q waves in I, avL, and V6 with an rS in V2. In comparison, the initial 10 msec vector in LBBB has two characteristics. First, the direction of activation is reversed, traveling from right to left (as there is absence of septal activation that results from a septal or median branch of the left bundle). Second, activation also travels from apex to base and to the right ventricular apex and free ventricular wall. However, the septum is a larger structure than the right ventricular free wall; thus, septal activation predominates. The resultant vector is to the left and usually anterior, resulting in loss of the normal q wave and initiation of a wide, slurred R wave in I, aVL, and V6. In addition, an rS or QS pattern is seen in V1. \"Pseudonormalization\" of septal depolarization in LBBB (ie, the reappearance of a q wave in I and V6) may reflect septal infarction.",
"     </li>",
"     <li>",
"      Mid-temporal leftward and posterior vector &mdash; Depolarization continues in the ordinary myocardial cells of the septum from apex to base. From 20 msec through 60 msec, spatial vectors are oriented to the left and posteriorly since the left ventricle is a leftward and posterior structure. The spatial vector that appears at 80 msec represents the mass of left ventricular myocardial depolarization, resulting in a signal of large amplitude. The amplitude of this signal is further increased by two factors: the terminal vectors are not countered by right ventricular forces since the right ventricle has already been depolarized; and the thick posterobasal portion of the left ventricle is activated before the thinner anterolateral wall.",
"     </li>",
"     <li>",
"      Terminal leftward vector &mdash; The terminal 10 msec vector and beyond result from depolarization of the anterolateral wall of the left ventricle which, as mentioned, is thinner than the posterobasal region, producing a small vector that is also directed to the left and posteriorly. Infarction of the anterolateral wall will decrease or actually reverse the direction of the terminal vector.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INTRAVENTRICULAR CONDUCTION DISTURBANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intraventricular conduction delay (IVCD) is the result of diffuse slowing of impulse conduction involving the entire His-Purkinje system, resulting in a generalized and uniform delay in activation of the ventricular myocardium. It is diagnosed in the presence of a QRS duration &gt;0.10 sec, and a QRS morphology that does not resemble either a typical LBBB or RBBB (",
"    <a class=\"graphic graphic_waveform graphicRef67274 \" href=\"UTD.htm?36/14/37096\">",
"     waveform 7",
"    </a>",
"    ). This can include the appearance of an RBBB in the limb leads and LBBB in the precordial leads, or the reverse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     BILATERAL BUNDLE BRANCH BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bilateral bundle branch block is caused by diffuse disease involving both bundles. If conduction within both bundles is completely blocked, no impulse is able to reach the ventricles and there is complete or third degree atrioventricular block. This leads to ventricular asystole or a ventricular escape rhythm.",
"   </p>",
"   <p>",
"    Bilateral bundle branch block also may be diagnosed when there are QRS complexes that occasionally have LBBB morphology and occasionally have RBBB morphology (",
"    <a class=\"graphic graphic_waveform graphicRef74362 \" href=\"UTD.htm?1/25/1428\">",
"     waveform 8",
"    </a>",
"    ). Often every other complex is a right or left bundle. This is also termed alternating bundle branch block, and is a worrisome sign for the development of complete heart block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INTERMITTENT BUNDLE BRANCH BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent bundle branch block, either right or left, is diagnosed on the ECG when there are occasional QRS complexes with a right or left bundle branch block morphology (but not both RBBB or LBBB), interspersed with QRS complexes that have a normal morphology (",
"    <a class=\"graphic graphic_waveform graphicRef72247 \" href=\"UTD.htm?27/39/28278\">",
"     waveform 9",
"    </a>",
"    ). Most often the intermittent bundle branch block is rate-related (as described below); thus, the RR intervals of the QRS complexes manifesting the bundle branch block are shorter when compared to the intervals of the normal QRS complexes. In other cases there is no rate related change in the QRS intervals, but the occurrence of the bundle branch block is a random or sporadic event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RATE RELATED BUNDLE BRANCH BLOCK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rate-related bundle branch block conduction is present when the QRS complex during a tachycardia is wider (usually &gt;0.12 seconds) when compared to the QRS duration during a slower sinus rhythm (",
"    <a class=\"graphic graphic_waveform graphicRef69284 \" href=\"UTD.htm?10/18/10532\">",
"     waveform 10",
"    </a>",
"    ). The aberrated QRS complexes may have the appearance of an RBBB, LBBB, IVCD, or from a bypass pathway; the important diagnostic feature is that the expression is usually influenced by the heart rate.",
"   </p>",
"   <p>",
"    Rate-related aberration is the result of slowed and delayed conduction within the bundle of His or the right or left bundle branches. This may be due to intrinsic disease of the conducting system or the depressant effects on conduction from antiarrhythmic drugs or hyperkalemia. If the rate of impulse stimulation is faster than the ability of that part of the conduction system to have repolarized from the prior impulse, the impulse may fail to conduct through part of the His Purkinje system (eg, only the right or left bundle). There is a critical heart rate above which the impulse is conducted by only one of the bundles, or is conducted with diffuse slowing throughout the His Purkinje system resulting in a nonspecific intraventricular delay. Thus, there is rate-related widening of the QRS complex occurring when the heart rate increases.",
"   </p>",
"   <p>",
"    The block is most often in the right bundle, which generally has a longer refractory period than the left bundle at similar heart rates; thus, a RBBB configuration is the most common morphology for the aberrated QRS complex. However, in patients with underlying heart disease, particularly coronary heart disease and fibrosis of the left septum, an LBBB morphology is not uncommon.",
"   </p>",
"   <p>",
"    Aberrancy may also be seen when a single atrial or junctional premature beat arrives at an RR interval (or rate) that is faster than the conduction system can conduct. The single premature beat is conducted aberrantly, usually when there is a critical coupling interval between the preceding sinus QRS complex and the premature beat; premature beats that occur later in diastole may be conducted normally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ashman's phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aberrancy is due in some cases to the physiologic changes of the conduction system refractory periods that are associated with the RR interval cycle length. A relationship exists in normal circumstances between the refractory period of the His Purkinje system and the heart rate: there is a decrease in the refractory period as the heart rate increases (even if abruptly); the refractory period lengthens as the heart rate slows. If there is a long RR interval (ie, due to a slow heart rate), followed by short interval (ie, a premature atrial complex), the signal from the short interval may encounter the refractory period of one of the bundles and demonstrate a right or left bundle branch block pattern.",
"   </p>",
"   <p>",
"    This is known as an Ashman&rsquo;s phenomenon. The Ashman&rsquo;s phenomenon is most commonly observed during atrial fibrillation when there are frequent episodes of long-short RR cycle lengths. However, it may occur whenever there is an abrupt change in rate (slow or long RR interval to fast or shorter RR interval). Hence, it may be seen with the abrupt onset of any supraventricular tachyarrhythmia. The aberrancy may be present for one beat and have a morphology that resembles a ventricular premature beat, or may involve several sequential complexes, which may give the appearance of ventricular tachycardia.",
"   </p>",
"   <p>",
"    It is often difficult to distinguish a premature ventricular complex from an aberrantly conducted or Ashman's beat in the presence of atrial fibrillation and in most cases is not clinically relevant, but some tips include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A premature ventricular beat is usually followed by a longer RR cycle, indicating the occurrence of a compensatory pause, the result of retrograde conduction into the AV node and antegrade block of the impulse originating in the atrium. If there is persistence of aberration at the same heart rate after the first beat, this suggests a ventricular origin.",
"     </li>",
"     <li>",
"      The absence of a long RR-short RR cycle associated with the wide or aberrated QRS complex suggests that it is of ventricular origin.",
"     </li>",
"     <li>",
"      Aberrancy is not present if, with inspection of a long ECG rhythm strip, there are RR cycle length combinations that are longer and shorter than those associated with the wide QRS complex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A ventricular origin is likely if there is a fixed coupling cycle between the normal and aberrated QRS complex when seen repeatedly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bradycardia dependent aberrancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with bradycardia-dependent aberrancy, the bundle branch block occurs after a longer pause or RR interval, which is the opposite of Ashman&rsquo;s phenomenon. This has been termed a phase 4 block. It is generally unexpected since there should be sufficient time for the bundles to recover and conduction to be normal after a long cycle. Three explanations have been postulated. One explanation is that the bundles are serving as pacemaker tissue and manifest spontaneous automaticity. This pacemaker tissue is no longer suppressed by stimuli from upper pacemakers when the cycle length is very prolonged, leading to generation of an impulse from one of the bundles and manifesting a block pattern in the other bundle. Another explanation is that the heart rate is slowed as a result of enhanced vagal tone, which also leads to impaired or slowed conduction through a bundle. Lastly, similar to paroxysmal atrioventricular block (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17749?source=see_link&amp;anchor=H5186175#H5186175\">",
"     \"ECG tutorial: Atrioventricular block\", section on 'Paroxysmal atrioventricular block'",
"    </a>",
"    ), there is disease in the bundle which leads to a spontaneous increase in phase 4 depolarization and sodium channel inactivation, preventing conduction down the bundle until it can be reset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H438225376\">",
"    <span class=\"h2\">",
"     Preexcitation syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of an accessory pathway that conducts antegrade, such as occurs in the Wolff-Parkinson-White or other preexcitation syndromes, may give the general appearance of a RBBB or LBBB pattern, though subtle differences are seen that demonstrate atypical features of RBBB or LBBB. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21171?source=see_link\">",
"     \"ECG tutorial: Preexcitation syndromes\"",
"    </a>",
"    .) In combination with a short PR interval, this is a reflection of a preexcitation, and RBBB and LBBB cannot be accurately diagnosed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16447690\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left anterior hemiblock or fascicular block is characterized by a pathologic left axis in the frontal limb leads, defined as an axis &gt;-45&ordm; to &gt;-60&ordm;, with a QRS &lt;0.12 seconds, a qR in lead aVL and a peak time to R wave in aVL &ge;0.045 seconds (",
"      <a class=\"graphic graphic_waveform graphicRef78636 \" href=\"UTD.htm?10/10/10402\">",
"       waveform 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Left posterior hemiblock is defined as a pathologic right axis, &gt;+90&ordm; (some authors use an even more rightward axis of 120&ordm;), when there is no other etiology. The QRS complex is negative (small R and deep S) in leads I and aVL, and positive (tall R wave) in leads III and aVF and a QRS &lt;0.12 seconds (",
"      <a class=\"graphic graphic_waveform graphicRef51923 \" href=\"UTD.htm?31/60/32705\">",
"       waveform 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      RBBB is characterized by (",
"      <a class=\"graphic graphic_waveform graphicRef65619 \" href=\"UTD.htm?7/46/7909\">",
"       waveform 5",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A RsR' complex in leads V1-2, often called a &ldquo;rabbit-ear&rdquo; pattern.",
"     </li>",
"     <li>",
"      A deep and broad S wave in leads I, aVL, and V5-6.",
"     </li>",
"     <li>",
"      The width of the QRS complex is &gt;0.12 seconds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LBBB is characterized by (",
"      <a class=\"graphic graphic_waveform graphicRef52836 \" href=\"UTD.htm?11/51/12085\">",
"       waveform 6",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Absent q waves in I and V5-6.",
"     </li>",
"     <li>",
"      A QS complex which is abnormal and widened in leads V1-V2.",
"     </li>",
"     <li>",
"      Time to peak R wave &gt; 0.06 seconds in leads V5-6.",
"     </li>",
"     <li>",
"      ST and T wave abnormalities.",
"     </li>",
"     <li>",
"      The width of the QRS complex is &gt;0.12 seconds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     ACKNOWLEDGMENT",
"    </strong>",
"    &nbsp;&mdash;&nbsp;The UpToDate editorial staff would&nbsp;like to thank Dr. Philip J. Podrid for his contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2126 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-1745D172DA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22038=[""].join("\n");
var outline_f21_33_22038=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16447690\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H438225084\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      LEFT ANTERIOR FASCICULAR BLOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LEFT POSTERIOR FASCICULAR BLOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RIGHT BUNDLE BRANCH BLOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Incomplete RBBB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Complete RBBB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LEFT BUNDLE BRANCH BLOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Incomplete LBBB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Complete LBBB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INTRAVENTRICULAR CONDUCTION DISTURBANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      BILATERAL BUNDLE BRANCH BLOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INTERMITTENT BUNDLE BRANCH BLOCK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RATE RELATED BUNDLE BRANCH BLOCK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ashman's phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bradycardia dependent aberrancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H438225376\">",
"      Preexcitation syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16447690\">",
"      SUMMARY",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2126\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2126|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?26/3/26677\" title=\"movie 1\">",
"      Conduction in right bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2126|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?10/10/10402\" title=\"waveform 1\">",
"      Left anterior fascicular block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?31/60/32705\" title=\"waveform 2\">",
"      Left posterior fascicular block",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?17/3/17460\" title=\"waveform 3\">",
"      Incomplete RBBB tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?42/12/43210\" title=\"waveform 4\">",
"      Right bundle branch block 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?7/46/7909\" title=\"waveform 5\">",
"      Right bundle branch block 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?11/51/12085\" title=\"waveform 6\">",
"      Left bundle branch block 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?36/14/37096\" title=\"waveform 7\">",
"      Intraventricular conduction delay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?1/25/1428\" title=\"waveform 8\">",
"      Bilateral BBB tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?27/39/28278\" title=\"waveform 9\">",
"      Intermittent BBB tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?10/18/10532\" title=\"waveform 10\">",
"      Aberrant conduction tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/21/17749?source=related_link\">",
"      ECG tutorial: Atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9317?source=related_link\">",
"      ECG tutorial: Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9283?source=related_link\">",
"      ECG tutorial: Physiology of the conduction system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/43/21171?source=related_link\">",
"      ECG tutorial: Preexcitation syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16886?source=related_link\">",
"      Left anterior fascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=related_link\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16420?source=related_link\">",
"      Left posterior fascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=related_link\">",
"      Right bundle branch block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_33_22039="Screening for bladder cancer";
var content_f21_33_22039=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for bladder cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22039/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22039/contributors\">",
"     Juan Antonio Jimenez, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22039/contributors\">",
"     Steven C Campbell, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22039/contributors\">",
"     J Stephen Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22039/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22039/contributors\">",
"     Seth P Lerner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22039/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22039/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22039/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/33/22039/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urothelial carcinoma of the bladder is the most frequently diagnosed cancer of the urinary tract other than prostate cancer, and its incidence has been slowly rising over the last several decades. When diagnosed early, the majority of bladder cancers are superficial (noninvasive). However, delayed diagnosis can be associated with high-grade muscle-invasive disease, which can quickly progress, metastasize, and become fatal.",
"   </p>",
"   <p>",
"    Screening refers to the detection of asymptomatic disease by testing either the general population or a targeted population of individuals known to be at increased risk. Screening for bladder cancer offers the potential to diagnose the disease in an early stage when treatment can lead to cure or significantly prolong the quality of life. However, it remains uncertain if screening can effectively achieve these goals.",
"   </p>",
"   <p>",
"    Screening is to be contrasted with surveillance, which refers to ongoing testing in patients who have been previously diagnosed and treated for cancer, to detect early recurrent disease. The issue of disease recurrence is of particular relevance for urothelial cancer. (See",
"    <a class=\"local\" href=\"#H8934265\">",
"     'Natural history'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The modalities that have been proposed for bladder cancer screening and results from the limited studies that have been conducted, will be reviewed here. An overview of the treatment of urothelial bladder cancer is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2759?source=see_link\">",
"     \"Overview of the management of urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, there were 386,000 cases of bladder cancer and 150,000 deaths related to bladder cancer in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/1\">",
"     1",
"    </a>",
"    ]. There is a 14-fold variation in bladder cancer incidence internationally, with the highest rates in Europe, North America, and Northern Africa. Among deaths due to solid cancers in the United States, bladder cancer ranks eighth [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/1\">",
"     1",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The factors associated with an increased risk of urothelial carcinoma have been well characterized in epidemiologic studies. The most important of these are chemical carcinogens, which may be derived from tobacco products or a range of occupational and environmental exposures, including aromatic amines and compounds encountered in the rubber and leather industries. Chronic infection with Schistosoma hematobium in some countries in Africa and the Middle East accounts for half of the incidence of bladder cancer in these areas; such bladder cancer is more likely to be squamous cell and carries a worse prognosis than urothelial cancer. Other risk factors include male sex, older age, Caucasian race, and personal or family history of bladder cancer. These risk factors are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Etiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bladder cancer is more frequent in men than women. Approximately 80 percent of cases of bladder cancer are diagnosed after the age of 60 years. These epidemiologic observations have defined older men, or older men who smoke, as the target group for initial screening studies. Workers with high levels of occupational exposure to known carcinogens constitute an even higher risk group. More intensive approaches to screening have been assessed for higher risk individuals. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'High-risk groups'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8934265\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of bladder cancer is highly variable and dependent upon the stage of disease (",
"    <a class=\"graphic graphic_table graphicRef53395 \" href=\"UTD.htm?25/52/26445\">",
"     table 1",
"    </a>",
"    ). Nonmuscle-invasive, low-grade tumors constitute approximately 65 percent of all new cases of urothelial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/2\">",
"     2",
"    </a>",
"    ] and are typically managed with endoscopic resection followed by surveillance cystoscopy. The risk of progression with such tumors is very low. Nonmuscle-invasive, high-grade disease (Stage Tis, Ta and T1) is managed with transurethral resection of bladder tumor (TURBT); however, 50 to 70 percent will recur and 10 to 30 percent progress to muscle-invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/3\">",
"     3",
"    </a>",
"    ]. For this reason, bladder-sparing local therapy is often combined with adjuvant intravesical immunotherapy with BCG. For Stage T1 or high-grade Ta disease, treatment includes re-resection prior to intravesical therapy. Muscle-invasive bladder cancer (Stage T2-T4a), without evidence of distant metastasis or node-positive disease, is typically treated with perioperative systemic chemotherapy along with radical cystectomy, urinary diversion, and pelvic lymphadenectomy.",
"   </p>",
"   <p>",
"    Environmental exposures are thought to cause most cases of bladder cancer. The urothelium that lines the entire urinary tract is continuously exposed to carcinogens that are excreted in the urine. This \"field cancerization\" effect is one hypothesis to explain the multifocal occurrence that is characteristic of urothelial carcinoma of the bladder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link\">",
"     \"Treatment of non-muscle-invasive bladder cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Etiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SCREENING MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ideal screening test for a broad population should be relatively inexpensive and easy to administer, with a high sensitivity and reasonable specificity. Specificity is particularly important when the prevalence of the disease is low. Options for bladder cancer screening include dipstick testing of the urine for microscopic hematuria, urine cytology, and screening for tumor-specific molecular markers that are shed into the urine.",
"   </p>",
"   <p>",
"    Cystoscopy is the gold standard for bladder cancer detection. Direct visualization of the urothelium guides the choice of sites for biopsy and transurethral resection. While office-based flexible cystoscopy has a high sensitivity and positive predictive value, it is not practical for general population screening due to its cost, procedural nature, and associated though small risks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\", section on 'Cystoscopy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a systematic review of screening for bladder cancer, among all three urine test modalities (dipstick for microscopic hematuria, cytology, biomarkers), the positive predictive value was less than 10 percent for screening in asymptomatic persons, including high-risk populations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Dipstick testing for hematuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with gross hematuria are considered to be symptomatic and require further evaluation. Such evaluation is not considered to be in the realm of screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link\">",
"     \"Etiology and evaluation of hematuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of microscopic hematuria, identified by dipstick testing or urinalysis, is variably reported in the general population, with reports ranging from 0.18 to 16.1 percent of the population in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/4\">",
"     4",
"    </a>",
"    ]. Microscopic hematuria may be intermittent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/5\">",
"     5",
"    </a>",
"    ]; however, microscopic hematuria is present in most patients with bladder cancer, even in the early stages of disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While dipstick testing for microscopic hematuria is inexpensive, widely available, and can be self-administered, the specificity of dipstick testing for bladder cancer is extremely low. For this reason, the American Urologic Association defines asymptomatic microscopic hematuria as three or more red blood cells per high-powered field [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/6\">",
"     6",
"    </a>",
"    ]. Overall, urologic cancers account for only approximately 5 percent of the cases of microscopic hematuria [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/5\">",
"     5",
"    </a>",
"    ]. The presence of blood in the urine is associated with a number of causes that are far more prevalent than bladder cancer in the general population (",
"    <a class=\"graphic graphic_figure graphicRef61296 \" href=\"UTD.htm?13/34/13870\">",
"     figure 1",
"    </a>",
"    ). Although the presence of microscopic hematuria in the general population has a low predictive value for urothelial carcinoma, the American Urologic Association 2012 guidelines recommend prompt urologic evaluation in all patients 35 years or older in whom benign causes have been ruled out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Urine cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The detection of cytologic changes in urothelial cells shed into the urine is a standard approach for detecting bladder cancer. In a systematic review of the literature, cytologic examination of the urine had a sensitivity of 34 percent and a specificity of up to 99 percent in detecting new and recurrent urothelial tumors in studies that included both screening and surveillance populations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=see_link&amp;anchor=H13#H13\">",
"     \"Clinical presentation, diagnosis, and staging of bladder cancer\", section on 'Urine cytology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urine cytology has not been widely used for bladder cancer screening because of its relatively low sensitivity, the need for a pathologist for interpretation, and its high cost. However, cytology remains an important technique for surveillance in those with a prior history of urothelial carcinoma and those with suspicious symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2554149\">",
"    <span class=\"h2\">",
"     Urine biomarkers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular testing for specific chromosomal changes and protein products unique to bladder cancer holds the promise of detecting early disease. Cellular alterations in malignant transformed cells (eg, upregulated oncogenes, downregulated tumor suppressor genes, changes in protein expression and receptors) occur before phenotypic changes can be seen by cystoscopy or cytology. Multiple urinary biomarkers are under development to detect early evidence of bladder malignancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40041?source=see_link\">",
"     \"Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary tumor-specific molecular markers primarily have been studied for their applicability in surveillance (ie, detection in individuals who have had prior nonmuscle-invasive urothelial cancers and are at risk for recurrent disease). Because of the lower disease prevalence in a screening population, even in those at increased risk, the use of biomarkers for screening requires greater specificity and lower cost than for surveillance. As an example, in one screening study using nuclear matrix protein 22 (NMP22 BladderChek) which included 1502 high-risk individuals with a history of &ge;10 years of smoking or &ge;15 years of work in a high-risk occupation, positive findings were reported in 85 individuals (5.7 percent); however, of the 69 who underwent cystoscopy, only two cases of noninvasive cancer and one case of marked atypia were identified [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technological advances in radiologic imaging and data processing have led to the exploration of three-dimensional reconstruction of the bladder. CT cystoscopy (&ldquo;virtual cystoscopy&rdquo;) seeks to reproduce the benefits of a direct examination in assessing bladder urothelium without instrumentation. Although this modality can identify some papillary bladder lesions, it appears less effective than cystoscopy for identifying carcinoma in-situ or flat minimally-invasive tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/9\">",
"     9",
"    </a>",
"    ]. A similar approach is currently used for screening of colorectal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=see_link&amp;anchor=H18#H18\">",
"     \"Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy\", section on 'Computed tomographic colonography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Current virtual imaging techniques for bladder cancer are neither sufficiently sensitive nor cost effective for use in screening. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     STUDIES OF SCREENING EFFECTIVENESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bladder cancer appears to be a potential candidate for screening, based upon its prevalence, the presence of known risk factors which permit the definition of a relatively high-risk group (eg, older male smokers), and the ease of administration and availability of urine tests that may detect asymptomatic disease in an early stage.",
"   </p>",
"   <p>",
"    It is not sufficient, however, to base screening recommendations upon findings that early stage disease can be identified. The high incidence of recurrent bladder cancer despite treatment of the initial noninvasive tumor makes the impact of an early diagnosis via a screening program uncertain. Screening effectiveness is best determined by randomized trials that compare outcomes for individuals randomly assigned to screening or no screening groups. Such randomized trials of bladder cancer screening are not available. In their absence, observational studies are subject to multiple confounders that influence which individuals undergo screening, as well as to lead-time bias, length-time bias, and overdiagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=see_link\">",
"     \"Evidence-based approach to prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Average-risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two relatively large studies have attempted to prospectively assess the impact of screening using urine dipstick testing for hematuria in healthy populations of older men [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/5,10\">",
"     5,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 1575 community-dwelling men aged &ge;50 years were tested repetitively for blood in the urine over a one year period [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/10\">",
"       10",
"      </a>",
"      ]. An additional 1940 men declined to participate in screening. Of the screened group, 258 (16 percent) were evaluated in more detail following the detection of hematuria. Workup identified 21 patients with bladder cancer (8 percent of those with hematuria, 1.3 percent of the entire cohort). Of these 21, 11 had low-grade lesions, 9 were high-grade, and 1 was invasive. At 14 years of follow-up, no deaths due to bladder cancer had occurred.",
"      <br/>",
"      <br/>",
"      The outcomes in these 21 men were compared with 509 patients with bladder cancer who were identified from a tumor registry. After 14 years of follow-up, significantly fewer bladder cancer deaths occurred in patients whose cancer was detected by screening compared to the registry group (0 of 21 patients versus 104 of 509 [0 versus 20 percent]), primarily accounted for by decreased mortality risk in screened patients with high-grade or invasive cancer. Overall mortality at 14 years was nonsignificantly lower in the screened patients with bladder cancer compared to registry patients (relative risk 0.80, 95% CI 0.48-1.32). Since this was not a randomized trial, the findings are subject to confounding, bias, and overdiagnosis (registry patients had clinically apparent cancer while screen-detected patients may never have developed symptomatic disease).",
"      <br/>",
"      <br/>",
"      Follow-up of 234 patients who originally had a negative evaluation for microscopic hematuria after screening was carried out at a minimum of 14 years after the original screening [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/11\">",
"       11",
"      </a>",
"      ]. Two patients subsequently developed bladder cancer, 7 and 11 years after their original presentation with microscopic hematuria.",
"     </li>",
"     <li>",
"      In another study, 2356 asymptomatic men aged &ge;60 years were screened at baseline and then weekly for 10 consecutive weeks at home using dipstick testing [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/5\">",
"       5",
"      </a>",
"      ]. Overall, 474 men had hematuria (20 percent), including 295 (12.5 percent) at baseline and 179 (7.6 percent) during the subsequent 10 weeks of home testing. Full evaluation was recommended for all patients with hematuria. Of the 265 patients who underwent an evaluation, asymptomatic bladder cancer was identified in 17 (0.7 percent of the screened population). None of the 17 had muscle-invasive disease at diagnosis, although three of the nine patients with high-grade disease eventually died of bladder cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above prospective observational studies reaffirm that the presence of hematuria lacks specificity for bladder cancer. Given the low prevalence of bladder cancer compared with other causes of hematuria, testing for hematuria",
"    <strong>",
"     cannot",
"    </strong>",
"    be recommended as a screening test for bladder cancer in the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     High-risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urothelial carcinoma is known to be associated with tobacco, aryl amines, and other chemical carcinogens. Workplace chemical exposure for workers in the chemical industry, rubber manufacturing, gas production, and several other occupations may increase the risk of developing bladder cancer as much as 100-fold above risk in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Etiology and risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urine cytology and cystoscopy have been used to screen workers who are at extremely high risk for developing bladder cancer due to occupational exposure to known urothelial carcinogens. Interpretation of studies of screening in these high-risk populations is difficult because of problems in assessing the extent of exposure, changes in screening methods over time, and the absence of randomized trials.",
"   </p>",
"   <p>",
"    Although several nonrandomized studies have documented a high incidence of bladder cancer in populations with heavy exposure to known carcinogens, these reports did not demonstrate that active screening alters the natural history of the disease in those who do develop bladder cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Canadian study of workers exposed to various",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/43/44724?source=see_link\">",
"       coal tar",
"      </a>",
"      derivatives in an aluminum production facility provides the most complete data in a very high risk population. Between 1970 and 1986, 79 cases of bladder cancer were diagnosed, including 19 who died of bladder cancer. Beginning in 1980, annual urinary cytology exams were performed, and cases diagnosed by screening were compared with cases diagnosed prior to the initiation of screening. In those diagnosed through this screening program, there was an increase in the percentage of noninvasive disease (77 versus 67 percent) following screening but this difference was not statistically significant. There was also a trend toward increased five year survival after screening (RR 0.54, 95% CI 0.20-1.48), although there was no adjustment for confounders and use of historical controls raises the potential that factors other than screening could account for any observed differences [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, a bladder cancer screening program was evaluated in 408 factory workers who had been exposed to beta-naphthylamine [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. Industrial exposure to this carcinogen is associated with a 20- to 30-fold excess mortality from bladder cancer. Over a 15-year period, 350 individuals were screened using a variety of modalities including dipstick urinalysis, cytology, and newer biomarkers as those became available. Bladder cancer was diagnosed in 1 percent of patients (one with carcinoma in situ and two with transitional cell papilloma). An additional 14 were diagnosed with dysplasia, two of whom eventually developed urothelial cancer.",
"     </li>",
"     <li>",
"      A study of a cohort of Chinese workers occupationally exposed to benzidine evaluated the use of urinary biomarkers (DNA ploidy, bladder tumor-associated antigen p300, and G- actin) on voided urine samples to identify risk groups for bladder cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/17\">",
"       17",
"      </a>",
"      ]. Among 1788 exposed and 373 nonexposed workers followed for six years, there were 28 bladder cancers in the exposed group and 2 in the non-exposed group. The risk of developing bladder cancer was 19.6 times higher (95% CI 8.0-47.9) for workers positive for either DNA ploidy or p300 and 81.4 times higher (95% CI 33.3-199.3) for workers positive for both markers, compared to workers negative for both markers. After an initial urine screen with biomarkers and cytology, workers were stratified into high risk (two positive markers or extremely high titers of one marker, hematuria, or positive Pap cytology), moderate risk (one positive biomarker), or low risk (all negative) groups and subsequent screening was based on the risk group. High-risk screening involved cystoscopy, urine cytology, and biomarkers every six months; moderate risk screening involved annual biomarkers only, and the low risk group was not rescreened for over three years. Twenty-three of the 28 cancers occurred in the high-risk group, and continuous longitudinal surveillance (cystoscopy, cytology, and biomarkers) was thus limited to 20 percent of the exposed group. Two of the 28 patients with bladder cancer died over the six year period. The study could not address whether early identification of bladder cancer had an impact on mortality. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22038659\">",
"    <span class=\"h1\">",
"     HARMS OF SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential harms of screening include false-positive test results leading to anxiety and subsequent diagnostic procedures. Follow-up for positive tests usually includes urine cytology, upper tract imaging, cystoscopy and possible biopsy, which is associated with the potential risk of perforation, bleeding, or infection. There are no direct data regarding the actual harms of bladder cancer screening [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/18\">",
"     18",
"    </a>",
"    ]. However, given the low positive predictive value of a positive screening test (&lt;10 percent), the burden of additional studies for false positive findings would affect a significant number of screened individuals.",
"   </p>",
"   <p>",
"    Additional harm may be related to the potential for overdiagnosis (identifying a tumor that would never have become clinically apparent in the patient&rsquo;s lifetime). Harm caused by overdiagnosis relates to morbidity and cost associated with unnecessary cancer treatment as well as psychologic harm from being diagnosed with cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115015\">",
"    <span class=\"h1\">",
"     RESEARCH GAPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US Preventive Services Task Force (USPSTF) has identified multiple areas of needed research to better define the risks and benefits of screening for bladder cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cohort studies to understand the natural history of early disease",
"     </li>",
"     <li>",
"      Studies that compare the accuracy of urine screening tests in representative populations",
"     </li>",
"     <li>",
"      Randomized trials (or case-control studies) that assess outcomes in screened versus unscreened populations",
"     </li>",
"     <li>",
"      Studies of the harms related to screening and treatment",
"     </li>",
"     <li>",
"      Studies comparing less toxic treatment protocols used early in treatment versus more toxic treatment used with development of advanced disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF EXPERT GROUPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is",
"    <strong>",
"     no",
"    </strong>",
"    major organization that recommends screening for bladder cancer in asymptomatic adults. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 2010 review of the evidence regarding screening for bladder cancer for the US Preventive Services Task Force (USPSTF) concluded that there is no high-quality evidence that screening adults for bladder cancer improves outcomes compared with no screening [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/2\">",
"       2",
"      </a>",
"      ]. The USPSTF issued revised recommendations in 2011, which concluded that current evidence is insufficient to assess the benefits or harms of screening [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/18\">",
"       18",
"      </a>",
"      ]. If screening is offered, patients should understand that there is uncertainty about benefits and harms.",
"     </li>",
"     <li>",
"      The American Academy of Family Physicians supports the recommendation of the USPSTF [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The National Cancer Institute (of the United States) notes inadequate evidence to determine whether screening for bladder cancer would impact mortality and fair evidence that screening would result in unnecessary procedures with associated morbidity [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The European Association of Urology recommends prevention of bladder cancer by eliminating active and passive smoking [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/21\">",
"       21",
"      </a>",
"      ]. For high risk populations, the guidelines state that &ldquo;concerns about feasibility and cost-effectiveness mean that routine application of screening has not yet been established&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The American Cancer Society does not include screening for bladder cancer on its list of recommended cancer screening [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22039/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1115048\">",
"    <span class=\"h1\">",
"     SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than one-half of patients initially diagnosed with superficial bladder cancer and managed with organ-sparing therapy will develop recurrent disease and many will progress to invasive disease. Early identification of recurrence is critical. The approach to surveillance in patients with a history of noninvasive urothelial carcinoma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link&amp;anchor=H42#H42\">",
"     \"Treatment of non-muscle-invasive bladder cancer\", section on 'Posttreatment management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urothelial carcinoma of the bladder is the second-most frequently diagnosed cancer of the urinary tract. Once urothelial carcinoma is invasive, it can quickly progress and metastasize. Factors associated with increased risk include exposure to chemical carcinogens (tobacco, occupational and environmental exposures), older age, and male sex. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonmuscle-invasive, low-grade tumors constitute approximately 65 percent of all new cases of urothelial carcinoma bladder cancer and have low risk of progression. High-grade nonmuscle-invasive disease has a 50 to 70 percent risk of recurrence and 10 to 30 percent risk of progression to muscle-invasive disease. (See",
"      <a class=\"local\" href=\"#H8934265\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Microscopic hematuria, identified by dipstick testing or urinalysis, is present in most patients with bladder cancer, even in the early stages of disease. However, microscopic hematuria is associated with a number of causes that are far more prevalent than bladder cancer in the general population and overall urologic cancers account for approximately 5 percent of cases of microscopic hematuria. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Dipstick testing for hematuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tests proposed for screening include urine dipstick, cytology, and urine biomarkers. The relatively low prevalence of bladder cancer in a screening population requires greater specificity and sensitivity than these tests provide. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Screening modalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no randomized trials to evaluate the effectiveness of screening for bladder cancer in preventing cancer mortality or limiting morbidity from treatment of early disease. Prospective studies confirm a low positive predictive value for screening in older men at average risk. Studies of screening in populations of industrial workers at high risk for bladder cancer confirm that screening can identify noninvasive bladder cancer, but it is not known whether screening has an impact on disease outcome. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Studies of screening effectiveness'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      screening for bladder cancer (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For individuals with an unusually high risk of bladder cancer due to known chemical exposure, particularly in the industrial setting, screening is a reasonable alternative. The optimal modality for screening is unknown for this population, but may include dipstick testing for microhematuria, urine cytology, or urine biomarkers. All individuals, and especially those with occupational exposures known to increase risk, should be strongly counseled to not smoke, and smokers should be treated for smoking cessation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Average-risk groups'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'High-risk groups'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Recommendations of expert groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with a history of treated urothelial carcinoma have a high likelihood of developing recurrent disease or a second primary. Surveillance is necessary in this setting to detect disease recurrence. The role of and approaches to surveillance are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=see_link&amp;anchor=H42#H42\">",
"       \"Treatment of non-muscle-invasive bladder cancer\", section on 'Posttreatment management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/2\">",
"      Chou R, Dana T. Screening adults for bladder cancer: a review of the evidence for the U.S. preventive services task force. Ann Intern Med 2010; 153:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/3\">",
"      Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/4\">",
"      Cohen RA, Brown RS. Clinical practice. Microscopic hematuria. N Engl J Med 2003; 348:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/5\">",
"      Britton JP, Dowell AC, Whelan P, Harris CM. A community study of bladder cancer screening by the detection of occult urinary bleeding. J Urol 1992; 148:788.",
"     </a>",
"    </li>",
"    <li>",
"     David R, Jones JS, Barocas DA, et al.. Diagnosis, evaluation and follow-up of asymptomatic microhematruia (AMH) in Adults: AUA Guideline. May 2012. file://www.auanet.org/content/media/asymptomatic_microhematuria_guideline.pdf (Accessed on October 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/7\">",
"      Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 2003; 61:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/8\">",
"      Lotan Y, Elias K, Svatek RS, et al. Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol 2009; 182:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/9\">",
"      Marini M, Stasolla A, D'Aprile MR, et al. CT cystoscopy in the evaluation of bladder tumors. J Exp Clin Cancer Res 2003; 22:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/10\">",
"      Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 2006; 107:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/11\">",
"      Madeb R, Golijanin D, Knopf J, et al. Long-term outcome of patients with a negative work-up for asymptomatic microhematuria. Urology 2010; 75:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/12\">",
"      Mayfield MP, Whelan P. Bladder tumours detected on screening: results at 7 years. Br J Urol 1998; 82:825.",
"     </a>",
"    </li>",
"    <li>",
"     Steineck G. Demographic and epidemiologic aspects of bladder cancer. In: Bladder Cancer Current Diagnosis and Treatment, Droller MJ (Ed), Humana Press Inc, Totowa, NJ 2001. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/14\">",
"      Th&eacute;riault GP, Tremblay CG, Armstrong BG. Bladder cancer screening among primary aluminum production workers in Quebec. J Occup Med 1990; 32:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/15\">",
"      Marsh GM, Leviton LC, Talbott EO, et al. Drake Chemical Workers' Health Registry Study: I. Notification and medical surveillance of a group of workers at high risk of developing bladder cancer. Am J Ind Med 1991; 19:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/16\">",
"      Marsh GM, Cassidy LD. The Drake Health Registry Study: findings from fifteen years of continuous bladder cancer screening. Am J Ind Med 2003; 43:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/17\">",
"      Hemstreet GP 3rd, Yin S, Ma Z, et al. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 2001; 93:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/18\">",
"      Moyer VA, U.S. Preventive Services Task Force. Screening for bladder cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2011; 155:246.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aafp.org/online/en/home/publications/news/news-now/health-of-the-public/20110819bladdercancer.html.",
"    </li>",
"    <li>",
"     Bladder and other urothelial cancers screening. file://www.cancer.gov/cancertopics/pdq/screening/bladder/HealthProfessional/page1 (Accessed on August 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22039/abstract/21\">",
"      Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59:997.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines on non-muscle invasive bladder cancer. European Association of Urology 2011. file://www.uroweb.org/gls/pdf/05_TaT1_Bladder_Cancer.pdf (Accessed on September 12, 2011).",
"    </li>",
"    <li>",
"     American Cancer Society guidelines for the early detection of cancer. file://www.cancer.org/Healthy/FindCancerEarly/CancerScreeningGuidelines/american-cancer-society-guidelines-for-the-early-detection-of-cancer (Accessed on September 13, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2977 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-201.211.0.116-256F03B06F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22039=[""].join("\n");
var outline_f21_33_22039=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8934265\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SCREENING MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Dipstick testing for hematuria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Urine cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2554149\">",
"      Urine biomarkers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      STUDIES OF SCREENING EFFECTIVENESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Average-risk groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      High-risk groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22038659\">",
"      HARMS OF SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1115015\">",
"      RESEARCH GAPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RECOMMENDATIONS OF EXPERT GROUPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1115048\">",
"      SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2977\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2977|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/34/13870\" title=\"figure 1\">",
"      Causes of hematuria by age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2977|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/52/26445\" title=\"table 1\">",
"      TNM staging bladder CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/47/20217?source=related_link\">",
"      Clinical presentation, diagnosis, and staging of bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/46/34537?source=related_link\">",
"      Evidence-based approach to prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2759?source=related_link\">",
"      Overview of the management of urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38042?source=related_link\">",
"      Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/11/40122?source=related_link\">",
"      Treatment of non-muscle-invasive bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40041?source=related_link\">",
"      Urine biomarkers for the detection of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_33_22040="Denosumab for osteoporosis";
var content_f21_33_22040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Denosumab for osteoporosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22040/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22040/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22040/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22040/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22040/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22040/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/33/22040/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is a fully human monoclonal antibody to the receptor activator of nuclear factor kappaB ligand (RANKL), an osteoclast differentiating factor. It inhibits osteoclast formation, decreases bone resorption, increases bone mineral density (BMD), and reduces the risk of fracture.",
"   </p>",
"   <p>",
"    This topic review will discuss the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    as a therapy for osteoporosis. Other treatments for osteoporosis are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15786?source=see_link\">",
"     \"Parathyroid hormone therapy for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The receptor activator of nuclear factor kappaB ligand (RANKL) is a member of the TNF superfamily of ligands and receptors that is essential for the function of bone-resorbing osteoclasts. RANKL interacts with a receptor (RANK) on both osteoclast precursors and osteoclasts. The",
"    <span class=\"nowrap\">",
"     RANKL/RANK",
"    </span>",
"    interaction results in activation, migration, differentiation, and fusion of hematopoietic cells of the osteoclast lineage to begin the process of bone resorption.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    , a fully human monoclonal antibody that specifically binds RANKL, blocks the binding of RANKL to RANK and thereby reduces the formation, function, and survival of osteoclasts, which results in decreased bone resorption and increased bone density. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=see_link\">",
"     \"Normal skeletal development and regulation of bone formation and resorption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECT ON BMD",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17343480\">",
"    <span class=\"h2\">",
"     Postmenopausal women",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    improves bone mineral density (BMD) in postmenopausal women with low BMD [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. This was best demonstrated in the FREEDOM trial in which 7868 postmenopausal women (60 to 90 years of age) with osteoporosis (T-scores between -2.5 and -4.0 at the lumbar spine [LS] or total hip [TH]) were randomly assigned to subcutaneous denosumab (60 mg every six months) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/1\">",
"     1",
"    </a>",
"    ]. After three years, denosumab improved BMD of the LS and TH compared with placebo (9.2 versus 0 percent and 4.0 versus -2.0 percent, respectively). In addition, biochemical markers of bone turnover were significantly reduced in patients taking denosumab.",
"   </p>",
"   <p>",
"    In the Freedom extension trial, 4550 participants (2343 active treatment, 2207 placebo) remained in the trial and received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    , 60 mg twice yearly. In the first two years of the extension (representing five years of continuous denosumab treatment for 1946 patients), there were additional gains in bone mineral density at the lumbar spine and hip (3.5 and 1.4 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    in 1189 postmenopausal women with low bone mineral density (T-score &le;-2.0 at the LS or hip) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/2\">",
"     2",
"    </a>",
"    ]. The patients were randomly assigned to denosumab (60 mg subcutaneously every six months) plus oral placebo or to oral alendronate (70 mg weekly) plus subcutaneous placebo injections every six months. After one year, bone density gains at the total hip (3.5 versus 2.6 percent), femoral neck (2.4 versus 1.8 percent), and LS (5.3 versus 4.2 percent) were slightly but significantly greater with denosumab [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/2\">",
"     2",
"    </a>",
"    ]. Denosumab was also associated with significantly greater reductions in biochemical markers of bone turnover than alendronate.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is effective in postmenopausal women who previously were treated with bisphosphonates. In one trial, 500 postmenopausal women (T-scores between -2.0 and -4.0) who previously received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    were randomly assigned to switch to denosumab (60 mg subcutaneously every six months) or to continue alendronate (70 mg weekly) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/7\">",
"     7",
"    </a>",
"    ]. After 12 months, there were small but significantly greater gains in BMD in women assigned to denosumab (TH 1.9 versus 1.0 percent, LS 3.0 versus 1.8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is also effective for the prevention of osteoporosis. In a two-year trial of 332 postmenopausal women with LS T-scores between -1.0 and -2.5 who were randomly assigned to denosumab (60 mg administered subcutaneously every six months) or placebo, denosumab improved BMD of the LS, TH, and radius compared with placebo (6.5 versus -0.6, 3.4 versus -1.1, and 1.4 versus -2.1 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17343487\">",
"    <span class=\"h2\">",
"     Men",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few trials evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    in men with osteoporosis that is unrelated to androgen deprivation therapy. In one such trial, 242 men (mean age 65 years, mean femoral neck T-score -1.9), were randomly assigned to denosumab (60 mg subcutaneously every six months) versus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/8\">",
"     8",
"    </a>",
"    ]. After 12 months, denosumab improved BMD at all sites compared with placebo (5.7 versus 0.9 percent, 2.4 versus 0.3 percent, and 2.1 versus 0 percent for lumbar spine, total hip, and femoral neck, respectively). Biochemical markers of bone turnover were significantly reduced in men taking denosumab.",
"   </p>",
"   <p>",
"    The utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    for the prevention of osteoporosis in men with nonmetastatic, hormone-sensitive prostate cancer and the role of denosumab in men with bone metastases from prostate cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H11#H11\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Denosumab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=see_link&amp;anchor=H19251250#H19251250\">",
"     \"Management of bone metastases in advanced prostate cancer\", section on 'Denosumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FRACTURE RISK REDUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to improving BMD,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    reduces fracture risk, as demonstrated by the results of the FREEDOM trial described in the preceding section [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. After three years of subcutaneous denosumab (60 mg every six months), the following significant benefits were noted with denosumab compared with placebo:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A lower rate of new vertebral fractures (cumulative incidence 2.3 versus 7.2 percent, relative risk 0.32, 95% CI 0.26-0.41).",
"     </li>",
"     <li>",
"      A lower rate of hip (0.7 versus 1.2 percent) and nonvertebral (6.5 versus 8.5 percent) fractures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the extension trial described above [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/6\">",
"     6",
"    </a>",
"    ], the incidence of fractures remained low in the long-term (five year)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    group (2.8 and 2.5 percent for new vertebral and nonvertebral fracture, respectively).",
"   </p>",
"   <p>",
"    There are few fracture data in men. In the trial described above, clinical fractures occurred in two and one subject in the placebo and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    treated groups, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/8\">",
"     8",
"    </a>",
"    ]. In another trial, denosumab reduced the risk of vertebral fractures (a secondary endpoint) in men with prostate cancer treated with androgen deprivation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/10\">",
"     10",
"    </a>",
"    ]. This trial is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H11#H11\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Denosumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the osteoporosis clinical trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    was generally well tolerated, without evidence of symptomatic hypocalcemia, osteonecrosis of the jaw, or atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/1-5,11\">",
"     1-5,11",
"    </a>",
"    ]. Overall, the most common adverse effects were back, extremity, and musculoskeletal pain, hypercholesterolemia, and cystitis, occurring with equal frequency in the denosumab and placebo groups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/12\">",
"     12",
"    </a>",
"    ]. In the FREEDOM trial, eczema (3.0 versus 1.7 percent), cellulitis requiring hospitalization (0.3 versus &lt;1.0 percent), and flatulence (2.2 versus 1.4 percent) were significantly more common in women assigned to denosumab than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/1\">",
"     1",
"    </a>",
"    ]. In the sixth year of the extension trial (described above), two cases of ONJ were observed in the long-term group [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/6\">",
"     6",
"    </a>",
"    ]. Rates of skin infection and hypocalcemia were low. There were no reports of atypical fractures. Longer-term safety data are unavailable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    trials, all women were supplemented with daily calcium (1000 mg) and vitamin D (400 to 800 Units). A small proportion of women in the denosumab trials had a decrease in the serum calcium level to &lt;8.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (2.1",
"    <span class=\"nowrap\">",
"     mmol/L;",
"    </span>",
"    1.7 versus 0.4 percent in the placebo group) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/12\">",
"     12",
"    </a>",
"    ]. The decrease was transient and there were no episodes of symptomatic hypocalcemia that required discontinuation of denosumab. Thus, in patients with normal renal function, adequately supplemented with calcium and vitamin D, hypocalcemia typically is not a concern.",
"   </p>",
"   <p>",
"    However, in patients with conditions that predispose to hypocalcemia, such as chronic kidney disease, malabsorption syndromes, or hypoparathyroidism, symptomatic hypocalcemia may occur. As an example, in a study of 55 patients with varying degrees of chronic kidney disease, the proportion of patients with serum calcium &lt;7.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    or symptomatic hypocalcemia was higher, occurring in 10 and 29 percent of subjects with creatinine clearance of 50 to 80 and &lt;30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/12\">",
"     12",
"    </a>",
"    ]. Hypocalcemia also occurred in 29 percent of patients on hemodialysis. The nadir in serum calcium occurs approximately 10 days after administration.",
"   </p>",
"   <p>",
"    Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    should not be given to patients with preexisting hypocalcemia until it is corrected. In addition, patients with conditions predisposing to hypocalcemia (ie, chronic kidney disease and creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    should be monitored for hypocalcemia. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Pretreatment evaluation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Oversuppression of bone remodeling",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    suppresses bone remodeling and the long-term consequences with regard to adverse outcomes, such as osteonecrosis of the jaw (ONJ), atypical fractures, and delayed fracture healing, are unknown. ONJ could theoretically occur in patients taking denosumab for osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H48#H48\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data in humans on the effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    on fracture healing. In murine studies, denosumab delayed the removal of cartilage and remodeling of the fracture callus, but it improved strength and stiffness of the healing fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Effects on immune system",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to suppressing osteoclastogenesis, RANKL functions within the immune system. Therefore, an important issue with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    is whether its inhibition of RANKL has potential infectious and neoplastic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/15\">",
"     15",
"    </a>",
"    ]. In the trials described above, the proportion of patients experiencing adverse events was similar among the placebo, denosumab, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    groups. However, in some [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/1,4,16\">",
"     1,4,16",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/2,3\">",
"     2,3",
"    </a>",
"    ] of the trials there were a greater number of infections requiring hospitalization (eg, diverticulitis, pneumonia, atypical pneumonia, appendicitis, cellulitis, and labyrinthitis) in the denosumab group. In the FREEDOM trial, eczema (3.0 versus 1.7 percent) and severe cellulitis requiring hospitalization (0.3 versus &lt;1.0 percent) were significantly more common in women assigned to denosumab versus placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/1\">",
"     1",
"    </a>",
"    ]. Pancreatitis has also been reported.",
"   </p>",
"   <p>",
"    Although in some early trials there was a nonsignificant increased number of cases of breast, pancreatic, gastrointestinal, ovarian, and uterine tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/3,17\">",
"     3,17",
"    </a>",
"    ], overall rates of adverse events of neoplasm were similar between treatment groups in subsequent trials, including the larger FREEDOM trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/1-4,16\">",
"     1-4,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CANDIDATES FOR THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Osteoporosis therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no head-to-head trials comparing the antifracture efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    with other available osteoporosis therapies (eg, oral and intravenous bisphosphonates, teriparatide). The reduction in vertebral fracture noted with denosumab is similar to the reductions reported for subcutaneous teriparatide and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    , and greater than that reported for oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    . However, these data are based upon clinical trials in different patient populations, not head-to-head comparison trials.",
"   </p>",
"   <p>",
"    Given the absence of long-term safety data and the availability of other agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    is not recommended for osteoporosis prevention. The US Food and Drug Administration (FDA) and the European Medicines Agency approved denosumab for the treatment of postmenopausal women with osteoporosis at high risk for fracture (history of osteoporotic fracture, multiple risk factors for fracture) or patients who have failed or are intolerant of other available osteoporosis therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/12,18\">",
"     12,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of definitive data comparing osteoporosis therapies, treatment decisions should be individualized. The individual's risk for fracture, presence of comorbid conditions, and personal preference are important for weighing the potential benefits and risks of osteoporosis therapies.",
"   </p>",
"   <p>",
"    There is no consensus on the optimal use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    . Some experts believe that denosumab should not be used as initial therapy for postmenopausal women with osteoporosis at high risk for fracture because of the availability of oral bisphosphonates, for which there are long-term safety and fracture prevention data. In addition, generic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    is less expensive. However, other experts disagree and would use denosumab as initial therapy for women at high risk for fracture who have difficulty with the dosing requirements of oral bisphosphonates or are unwilling to take bisphosphonates. In addition, denosumab may have a role in patients who are intolerant of or unresponsive to other therapies and in those with impaired renal function. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Use in chronic kidney disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are few studies evaluating the benefits and risks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    in men with osteoporosis that is unrelated to androgen deprivation therapy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Other possible uses'",
"    </a>",
"    below.) Denosumab may benefit men with other causes of osteoporosis, but until more robust fracture data are available, we do not recommend denosumab for the initial treatment of men with osteoporosis who are not undergoing androgen deprivation therapy. However, denosumab may have a role in men who are intolerant of or unresponsive to other therapies and in those with impaired renal function.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is not intended for use in premenopausal women or children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other possible uses",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men receiving androgen deprivation therapy &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       Denosumab",
"      </a>",
"      has also been shown to prevent osteoporosis and vertebral fracture in men with nonmetastatic prostate cancer receiving androgen deprivation therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H11#H11\">",
"       \"Side effects of androgen deprivation therapy\", section on 'Denosumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women undergoing breast cancer treatment &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       Denosumab",
"      </a>",
"      increased bone density in postmenopausal osteopenic women receiving adjuvant aromatase inhibitor therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37545?source=see_link&amp;anchor=H20#H20\">",
"       \"Evaluation and management of aromatase inhibitor-induced bone loss\", section on 'Denosumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bone metastases &mdash; In a trial evaluating",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      for the treatment of bone metastases in patients with breast cancer, denosumab was as effective as zoledronic acid in reducing the risk of skeletal related complications, such as fracture, pain, and hypercalcemia. This topic is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31737?source=see_link&amp;anchor=H5#H5\">",
"       \"Mechanisms of bone metastases\", section on 'Osteoclasts'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients undergoing treatment for multiple myeloma &mdash; In preliminary studies,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      significantly reduced bone turnover in patients with multiple myeloma and radiologically confirmed bone lesions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link&amp;anchor=H8#H8\">",
"       \"Treatment of the complications of multiple myeloma\", section on 'Prevention of skeletal events'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of patients who may receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    is the same as the evaluation recommended for all patients with osteoporosis. The general evaluation for secondary causes of osteoporosis is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have hypocalcemia should not receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    until hypocalcemia is corrected. Patients with vitamin D deficiency should be replaced with vitamin D prior to administering denosumab. In addition, all patients should be adequately supplemented with calcium and vitamin D. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=see_link\">",
"     \"Treatment of vitamin D deficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    suppresses bone remodeling and therefore may contribute to adverse outcomes, such as osteonecrosis of the jaw (ONJ). Pretreatment considerations are the same as those for bisphosphonates, which also suppress bone remodeling and have been associated with an increased risk of ONJ. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H48#H48\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link&amp;anchor=H1928329#H1928329\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\", section on 'Osteonecrosis of the jaw'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    (60 mg) is administered by subcutaneous injection once every six months. It may be administered in the upper arm, thigh, or the abdomen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/12\">",
"     12",
"    </a>",
"    ]. It is available in a single-use prefilled syringe or a single-use vial. The vial requires a 27-gauge needle with syringe to withdraw and inject the 1 mL dose. Denosumab should be stored in the refrigerator and brought to room temperature by removing from the refrigerator for 15 to 30 minutes before administration.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is not renally excreted and, therefore, dose adjustments for chronic kidney disease are not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Use in chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    , unlike bisphosphonates, is not cleared by the kidney and as a consequence there is no restriction of its use in patients with creatinine clearances below 35",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    for whom bisphosphonates are considered contraindicated [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/11\">",
"     11",
"    </a>",
"    ]. In the FREEDOM trial described above, there was no exclusion criterion based upon serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/1\">",
"     1",
"    </a>",
"    ]. However, women were excluded if they had hyperparathyroidism, ie, women with renal dysfunction resulting in secondary hyperparathyroidism were not treated with denosumab.",
"   </p>",
"   <p>",
"    In a post-hoc analysis of the FREEDOM trial data, stratified by level of kidney function,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    was effective in reducing fracture risk and was not associated with an increase in adverse events, including changes in estimated glomerular filtration rate (eGFR), among women with impaired kidney function (eGFR &ge;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/20\">",
"     20",
"    </a>",
"    ]. There were only 73 women with an eGFR of 15 to 29",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (stage 4 chronic kidney disease) and no women with an eGFR below 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    (stage 5). Within the subgroup of women with stage 4 chronic kidney disease, there were too few events (four vertebral and three nonvertebral fractures) to draw any conclusions. Therefore, there is inadequate data with regard to fracture prevention efficacy in those with more severe kidney disease resulting in secondary hyperparathyroidism and in late stage renal disease (stage 4 and 5). In addition, the lack of published data on safety in this population suggests caution when using the agent in this group as well as certainty that patients in this category who fracture have osteoporosis and not some form of renal bone disease. More careful monitoring of serum calcium is also required. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Hypocalcemia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H16\">",
"     'Monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic kidney disease (creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    including patients receiving dialysis) are at higher risk for hypocalcemia following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    administration than patients with normal renal function. Calcium should be measured in such patients approximately 10 days after denosumab administration. Monitoring of serum calcium is not required in patients with normal renal function.",
"   </p>",
"   <p>",
"    Because serious infections and skin reactions were reported more frequently in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    than in the placebo group, patients should be advised to seek medical attention if they develop signs of an infection or skin reaction. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Monitoring the bone density response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    therapy is similar to the monitoring of other osteoporosis therapies. Frequency of BMD measurements is variable, but most investigators would not consider a follow up BMD for at least two years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Monitoring the response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Discontinuation of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data on the ideal duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    therapy or on sequential therapy with other osteoporosis agents.",
"   </p>",
"   <p>",
"    The effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    on bone density and bone remodeling are reversible with discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/16,21,22\">",
"     16,21,22",
"    </a>",
"    ]. This was illustrated by the results of an extension study of a phase 2 trial in which postmenopausal women were randomly assigned to receive denosumab (variable dosing), open label",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    (70 mg weekly) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. After 24 months, subjects receiving denosumab either continued treatment (60 mg every six months) for an additional 24 months (n = 231), discontinued therapy for 24 months (n = 47), or discontinued therapy for 12 months and then reinitiated denosumab for 12 months (n = 41) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22040/abstract/16\">",
"     16",
"    </a>",
"    ]. Subjects (n = 47) assigned to alendronate discontinued therapy and were followed, and the placebo group (n = 46) was continued. Sixty-four percent of the original cohort completed 48 months of treatment.",
"   </p>",
"   <p>",
"    Continuous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    treatment (four years) increased BMD at the LS (9.4 to 11.8 percent) and total hip (4.0 to 6.1 percent), whereas discontinuation of denosumab for 24 months resulted in decreases in LS (-6.6 percent) and total hip (-5.3 percent) BMD comparable to the gains previously achieved during 24 months of therapy. Markers of bone turnover increased within three to six months after discontinuation of denosumab to values above baseline, but were similar to baseline values within 24 months of discontinuing therapy.",
"   </p>",
"   <p>",
"    In postmenopausal women who were retreated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    12 months after discontinuing therapy, there was an increase in LS (9.0 percent) and total hip (3.9 percent) BMD over the 12 month retreatment phase. Retreatment also resulted in a rapid decrease in markers of bone turnover, such that values were similar to those of the continuous treatment group. Hence, denosumab has a more rapid on-off effect on bone than the bisphosphonates. Discontinuation results in bone loss within a relatively short time, whereas discontinuation of bisphosphonates does not lead to immediate bone loss. There are no data to determine whether fracture risk is increased during bone loss which occurs after discontinuation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H11271460#H11271460\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Alendronate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    inhibits RANKL, a protein involved with osteoclastogenesis. Denosumab increases BMD and reduces the risk of fracture. It is administered as a subcutaneous injection twice yearly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The exact role for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      among the other agents for osteoporosis management is unclear. There are no head-to-head trials comparing the antifracture efficacy of denosumab with other available osteoporosis therapies. Given the absence of long-term safety data and availability of other agents, denosumab is not recommended for the prevention of osteoporosis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Osteoporosis therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of definitive data comparing osteoporosis therapies, treatment decisions for patients with osteoporosis should be individualized. The individual's risk for fracture, presence of comorbid conditions, and personal preference are important for weighing the potential benefits and risks of osteoporosis therapies. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Osteoporosis therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For postmenopausal women with uncomplicated osteoporosis (T-score below -2.5), we suggest",
"      <strong>",
"       not",
"      </strong>",
"      using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      as initial therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Osteoporosis therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We prefer oral bisphosphonates as initial therapy because of their efficacy, favorable cost, and the availability of long-term safety data. However, denosumab could be used as initial therapy in select patients at high risk for fracture, such as older patients who have difficulty with the dosing requirements of oral bisphosphonates.",
"      <br/>",
"      <br/>",
"      In addition, denosumab may have a role in patients who are intolerant of or unresponsive to other therapies and in those with impaired renal function.",
"     </li>",
"     <li>",
"      In the absence of fracture prevention data, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      for the initial treatment of osteoporosis in men who are not receiving androgen deprivation therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). However, denosumab may have a role in men who are intolerant of or unresponsive to other therapies and in those with impaired renal function. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Osteoporosis therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Use of denosumab in men receiving androgen deprivation therapy is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H11#H11\">",
"       \"Side effects of androgen deprivation therapy\", section on 'Denosumab'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the absence of data, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      in premenopausal women or children (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Osteoporosis therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pretreatment considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have hypocalcemia should not receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    until hypocalcemia is corrected. Patients with vitamin D deficiency should be replaced with vitamin D prior to administering denosumab. In addition, all patients should be adequately supplemented with calcium and vitamin D. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Pretreatment evaluation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with chronic kidney disease (creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      including patients receiving dialysis) are at higher risk for hypocalcemia following",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      administration than patients with normal renal function. Calcium should be measured in such patients approximately 10 days after denosumab administration. Monitoring of serum calcium is not required in patients with normal renal function. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Other possible uses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because serious infections and skin reactions were reported more frequently in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      than in the placebo group, patients should be advised to seek medical attention if they develop signs of an infection or skin reaction. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monitoring the bone density response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/53/21335?source=see_link\">",
"       denosumab",
"      </a>",
"      therapy is similar to the monitoring of other osteoporosis therapies. Frequency of BMD measurements is variable, but most investigators would not consider a follow-up BMD for at least two years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H31#H31\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Monitoring the response to therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/1\">",
"      Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/2\">",
"      Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/3\">",
"      McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/4\">",
"      Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008; 93:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/5\">",
"      Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007; 22:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/6\">",
"      Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res 2012; 27:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/7\">",
"      Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/8\">",
"      Orwoll E, Teglbj&aelig;rg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012; 97:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/9\">",
"      Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011; 96:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/10\">",
"      Smith MR, Egerdie B, Hern&aacute;ndez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/11\">",
"      Khosla S. Increasing options for the treatment of osteoporosis. N Engl J Med 2009; 361:818.",
"     </a>",
"    </li>",
"    <li>",
"     Highlights of prescribing information, Prolia (denosumab). www.pi.amgen.com/united_states/prolia/prolia_pi.pdf (Accessed on June 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/13\">",
"      Rachner TD, Platzbecker U, Felsenberg D, Hofbauer LC. Osteonecrosis of the Jaw After Osteoporosis Therapy With Denosumab Following Long-term Bisphosphonate Therapy. Mayo Clin Proc 2013; 88:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/14\">",
"      Gerstenfeld LC, Sacks DJ, Pelis M, et al. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. J Bone Miner Res 2009; 24:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/15\">",
"      Whyte MP. The long and the short of bone therapy. N Engl J Med 2006; 354:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/16\">",
"      Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 2008; 43:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/17\">",
"      Anastasilakis AD, Toulis KA, Goulis DG, et al. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis. Horm Metab Res 2009; 41:721.",
"     </a>",
"    </li>",
"    <li>",
"     European Medicines Agency, Prolia (denosumab). file://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001120/human_med_001324.jsp&amp;murl=menus/medicines/medicines.jsp&amp;jsenabled=true (Accessed on August 18, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/19\">",
"      Block GA, Bone HG, Fang L, et al. A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Miner Res 2012; 27:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/20\">",
"      Jamal SA, Ljunggren O, Stehman-Breen C, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res 2011; 26:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/21\">",
"      Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22040/abstract/22\">",
"      Brown JP, Dempster DW, Ding B, et al. Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. J Bone Miner Res 2011; 26:2737.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2067 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-704953041C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22040=[""].join("\n");
var outline_f21_33_22040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECT ON BMD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17343480\">",
"      Postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17343487\">",
"      Men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FRACTURE RISK REDUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Oversuppression of bone remodeling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Effects on immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CANDIDATES FOR THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Osteoporosis therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other possible uses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Use in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Discontinuation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pretreatment considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37545?source=related_link\">",
"      Evaluation and management of aromatase inhibitor-induced bone loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/36999?source=related_link\">",
"      Management of bone metastases in advanced prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/63/31737?source=related_link\">",
"      Mechanisms of bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/5/34906?source=related_link\">",
"      Normal skeletal development and regulation of bone formation and resorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/26/15786?source=related_link\">",
"      Parathyroid hormone therapy for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_33_22041="Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection";
var content_f21_33_22041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of Streptococcus bovis infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22041/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22041/contributors\">",
"     Howard S Gold, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22041/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22041/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22041/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22041/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/33/22041/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcus bovis is a gram-positive coccus that is an important cause of bacteremia and infective endocarditis (IE) in adults. Because there is a strong association between infections with S. bovis and colonic neoplasms and other lesions of the gastrointestinal tract, evaluation of the gastrointestinal tract with colonoscopy is important for patients with infections due to this organism [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Members of the S. bovis group include Streptococcus gallolyticus and Streptococcus infantarius; S. gallolyticus includes some strains previously classified as S. bovis biotype I (S. gallolyticus subspecies gallolyticus) and",
"    <span class=\"nowrap\">",
"     II/2",
"    </span>",
"    (S. gallolyticus subspecies pasteurianus) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/2\">",
"     2",
"    </a>",
"    ]. S. infantarius includes strains identified as S. bovis biotype",
"    <span class=\"nowrap\">",
"     II/1",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These species and subspecies differ in their microbiology, pathogenesis, and epidemiology. Most clinical microbiology laboratories in the United States use automated testing equipment or other methods to identify these organisms to the species and subspecies level. However, some laboratories continue to report them under the common name S. bovis or S. bovis group [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Associations with endocarditis and colonic neoplasm are most closely linked to S. gallolyticus subspecies gallolyticus (S. bovis biotype I) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ]. S. bovis biotype II bacteremias may be more associated with biliary tract disease and more likely to be polymicrobial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. However, the published literature regarding these organisms does not always distinguish S. bovis isolates to the biotype",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subspecies level consistently [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and therapy of Streptococcus bovis infection will be reviewed here. The microbiology, pathogenesis, and epidemiology of S. bovis infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29926?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24505889\">",
"    <span class=\"h1\">",
"     CLINICAL ASSOCIATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24505897\">",
"    <span class=\"h2\">",
"     Association with endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. bovis accounts for 2 to 6 percent of streptococcal bloodstream isolates from hospitalized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]; the gastrointestinal tract is the most likely portal of entry [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/10\">",
"     10",
"    </a>",
"    ]. Almost all bacteremias caused by S. bovis are clinically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/2\">",
"     2",
"    </a>",
"    ]. In a report of 92 patients with S. bovis bacteremia, 28 percent were found to have infective endocarditis (IE) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In studies that discriminate to the subspecies level, IE was observed in 43 to 100 percent of patients infected with S. gallolyticus subspecies gallolyticus (S. bovis biotype I). The proportion of patients with IE and infection due to S. bovis biotype II (S. gallolyticus subspecies pasteurianus and S. infantarius) was 8 to 29 percent, similar to viridans streptococci in some series [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/1,12\">",
"     1,12",
"    </a>",
"    ]. S. bovis bacteremia in the absence of IE was frequently associated with S. bovis biotype II (67 to 69 percent), polymicrobial bloodstream infection (44.0 to 53.5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/7,12\">",
"     7,12",
"    </a>",
"    ], and biliary tract disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. In one series biliary tract disease was associated with half of bacteremias due to S. bovis biotype II (S. gallolyticus subspecies pasteurianus and S. infantarius) and 5 percent of bacteremias due to S. bovis biotype I (S. gallolyticus subspecies gallolyticus) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Patients with S. bovis bacteremia should undergo an echocardiogram. This is most critical for patients with bacteremia due to isolates of S. gallolyticus subspecies gallolyticus and isolates not identified to the subspecies level. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An analysis of a large IE isolate database demonstrated that S. bovis caused 6 percent of infective endocarditis cases (ranging from 10 percent in Europe to 2 percent of cases in North America) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/13\">",
"     13",
"    </a>",
"    ]. Patients with S. bovis endocarditis are typically older and less likely than other patients with IE to have predisposing risk factors such as intravenous drug use or structural heart disease. Other issues related to the epidemiology of infection are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29926?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24506924\">",
"    <span class=\"h2\">",
"     Association with colonic neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association between S. bovis infection and colonic neoplasia is well described. The association with colonic neoplasia is strongest for S. gallolyticus subspecies gallolyticus (S. bovis biotype I) infections and for cases of IE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/1\">",
"     1",
"    </a>",
"    ], but colonic neoplasia has also been observed in the setting of S. bovis infection at other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/1,14\">",
"     1,14",
"    </a>",
"    ]. The proportion of patients with colonic neoplasia is significantly higher in the setting of S. bovis IE compared with viridans streptococcal IE (63 versus 18 percent of patients undergoing colonoscopy), but the proportion of patients with colonic carcinoma may be somewhat lower than for patients with Clostridium septicum bacteremia (28 percent had colorectal cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. The reason for this association is not fully understood, but may be attributed to the presence of proteins in S. gallolyticus subspecies gallolyticus (S. bovis biotype I) that bind to ligands that are overexpressed in colonic neoplasms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29926?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial study describing the association noted that S. bovis was recovered from fecal cultures in 56 percent of patients with colon cancer, compared with 10 percent of individuals from a control group with no gastrointestinal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/15\">",
"     15",
"    </a>",
"    ]. However, some subsequent studies found no difference in carriage rates between gastrointestinal tract carcinomas and controls [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In studies of patients with S. bovis bacteremia or endocarditis, colon cancer has been observed in 16 to 32 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/10,11,15,16,18-21\">",
"     10,11,15,16,18-21",
"    </a>",
"    ]. Correlation between S. bovis infection and other lesions of the gastrointestinal tract has also been described. Adenomas are more commonly associated with S. bovis infection than carcinomas (median prevalence of 43 versus 18 percent in studies included in a meta-analysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/2\">",
"     2",
"    </a>",
"    ]. Other gastrointestinal tract lesions include premalignant or benign polyps, lymphoma, colitis, and mechanical abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/10,11,18,22,23\">",
"     10,11,18,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variability in the reported incidence of colon cancer in patients with S. bovis bacteremia or endocarditis may be due to several factors. Differences in organism biotype may be responsible for some of this variability [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ]. A meta-analysis demonstrated that patients with S. bovis biotype I infection (S. gallolyticus subspecies gallolyticus) had a strongly increased risk of colorectal cancer (pooled odds ratio [OR] 7.26; 95 percent confidence interval [CI] 3.94-13.36) and endocarditis (pooled OR 16.61; 95 percent CI 2.03-6.81) compared with patients with S. bovis biotype II infection (S. gallolyticus subspecies pasteurianus and S. infantarius) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/1\">",
"     1",
"    </a>",
"    ]. The rigor of colonic inspection (proportion of patients undergoing full colonoscopy) has been cited as a potential factor in underestimation of the association between S. bovis bacteremia and colon cancer in some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. In addition, the impact of the marked geographic variability in the epidemiology of S. bovis bacteremia and endocarditis on the probability of colonic lesions is unknown. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29926?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Identification of S. bovis infection should prompt colonoscopy to evaluate for carcinoma or other colonic lesions. (See",
"    <a class=\"local\" href=\"#H1612075403\">",
"     'Colonoscopy'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24506986\">",
"    <span class=\"h2\">",
"     Association with liver disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. bovis infection has been associated with liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/11,19,25-27\">",
"     11,19,25-27",
"    </a>",
"    ]. In a study of 199 patients with IE, advanced liver disease (primarily hepatitis C related) was significantly more likely in patients with S. bovis biotype I endocarditis than patients with non&ndash;S. bovis endocarditis (56 versus 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/25\">",
"     25",
"    </a>",
"    ]. In the setting of hepatic disease, dysfunction of the reticuloendothelial system may compromise bacterial clearance, allowing entry of organisms into the portal or systemic circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1612075351\">",
"    <span class=\"h2\">",
"     Bacteremia and endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations of infective endocarditis (IE) due to S. bovis are comparable with manifestations of IE caused by other organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/18,28-32\">",
"     18,28-32",
"    </a>",
"    ]. The presentation is usually subacute, but occasionally acute onset occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/32\">",
"     32",
"    </a>",
"    ]. Involvement of more than one valve has been associated with S. bovis endocarditis more frequently than other oral streptococci (14.0 versus 5.5 percent in one series including 647 cases of streptococcal IE) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/25,29,30,33\">",
"     25,29,30,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with S. bovis IE tend to have relatively large vegetations. In a study including 206 patients with definite IE by Duke criteria, vegetations &gt;10 mm were observed more frequently in patients with S. bovis IE compared with IE caused by other streptococci and nonstreptococcal pathogens (50 percent versus 20 and 34 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S. bovis infection may be highly destructive, resulting in valve perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/28\">",
"     28",
"    </a>",
"    ] or invasive disease with cardiac septal or valvular ring abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/18\">",
"     18",
"    </a>",
"    ]. In one case series, infiltration of the left ventricle was more often observed in the setting of IE due to S. bovis than other causes of IE (36 versus 10 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/30\">",
"     30",
"    </a>",
"    ]. Patients with S. bovis in this study were older, had a longer interval prior to diagnosis, and required surgery more often than patients with IE due to other organisms.",
"   </p>",
"   <p>",
"    Data are conflicting as to whether embolic events are more common in IE caused by S. bovis compared with other pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/18,25,29,30,32,35-37\">",
"     18,25,29,30,32,35-37",
"    </a>",
"    ]. A few series have noted a predilection for spondylodiscitis as a complication of S. bovis IE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/12,25\">",
"     12,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Other sites of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. bovis may cause septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/38\">",
"     38",
"    </a>",
"    ]. Biotype",
"    <span class=\"nowrap\">",
"     II/2",
"    </span>",
"    (S. gallolyticus subspecies pasteurianus) has been particularly associated with neonatal sepsis, with or without meningitis; this entity may be clinically indistinguishable from neonatal infection caused by S. agalactiae [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29926?source=see_link&amp;anchor=H2#H2\">",
"     \"Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Meningitis has been described in association with S. bovis bacteremia and endocarditis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/14,37,42-44\">",
"     14,37,42-44",
"    </a>",
"    ]. Such infections may be more likely in immunocompromised hosts, including patients with diabetes and chronic renal failure, immunosuppressive therapy, and human immunodeficiency virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Brain abscesses have been reported as a result of monomicrobial infection or polymicrobial infection together with Fusobacterium, Peptostreptococcus, and group G streptococcus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other sites of S. bovis infection include septic arthritis, prosthetic joint infection, vertebral discitis, and endophthalmitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. S. bovis has also been isolated from a deep neck abscess, infected ascites, and peritoneal dialysis fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. S. bovis can cause spontaneous bacterial peritonitis in the setting of hepatic cirrhosis, in the absence of colonic neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of infection due to S. bovis is made via the isolation of the organism from blood, other body fluid, or tissue. Gram-positive cocci that grow on agar in the presence of 40 percent bile and that hydrolyze esculin are very likely to be group D streptococci (S. bovis group) or enterococci [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/27,56\">",
"     27,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Determination of the Lancefield group is not usually necessary, nor does it not detect all S. bovis isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/27\">",
"     27",
"    </a>",
"    ]. S. bovis typically fails to grow in 6.5 percent NaCl broth, cannot hydrolyze arginine, and is PYR (pyrrolidonyl arylamidase) negative, which assists in distinguishing it from enterococci [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/6,32\">",
"     6,32",
"    </a>",
"    ]. Occasionally, streptococci of the viridans group (especially Streptococcus salivarius) are misidentified as S. bovis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29926?source=see_link\">",
"     \"Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    S. bovis may be differentiated from viridans streptococci and identified to the",
"    <span class=\"nowrap\">",
"     species/subspecies",
"    </span>",
"    level using commercially available kits and automating testing equipment found in most US clinical microbiology laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/6,27,57,58\">",
"     6,27,57,58",
"    </a>",
"    ]. These distinctions have clinical significance, as S. salivarius is not usually associated with neoplasia and is a relatively frequent blood culture contaminant. In one study of 68 patients with positive cultures growing S. bovis biotype I, S. bovis biotype II, and S. salivarius, the frequency of IE was 94, 18, and 10 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/6\">",
"     6",
"    </a>",
"    ]. The incidence of malignant or premalignant colonic lesions was 71, 18, and 3 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29926?source=see_link&amp;anchor=H2#H2\">",
"     \"Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ANTIBIOTIC RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. bovis is susceptible to a number of antibiotics and is substantially more susceptible to penicillin and other beta-lactam antibiotics than enterococci (",
"    <a class=\"graphic graphic_table graphicRef77155 graphicRef52108 \" href=\"UTD.htm?13/16/13582\">",
"     table 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/32\">",
"     32",
"    </a>",
"    ]. However, some studies have noted MICs exceeding \"fully susceptible\" streptococci for the purposes of selecting treatment for endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/8,59-61\">",
"     8,59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While most strains of S. bovis appear to be killed at concentrations of penicillin near the MIC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/32,62\">",
"     32,62",
"    </a>",
"    ], occasional isolates display tolerance to the lethal effects of penicillin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other cell wall-active agents [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/31,32,63,64\">",
"     31,32,63,64",
"    </a>",
"    ]. For these isolates, killing measured in vitro is",
"    <strong>",
"     not",
"    </strong>",
"    achieved at concentrations that are readily attainable in serum during clinical treatment. However, testing for antibiotic tolerance is not available in most clinical microbiology labs and determination of minimum bactericidal concentrations (MBCs) is not performed routinely.",
"   </p>",
"   <p>",
"    Resistance among S. bovis isolates to non-beta-lactam antibiotic classes is relatively common [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Among 128 S. gallolyticus clinical isolates, 78 percent were resistant to tetracyclines, 59 percent to macrolides, 50 percent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , 37 percent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , and 35 percent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/65\">",
"     65",
"    </a>",
"    ]. Nearly all of the aminoglycoside-resistant isolates (due to the presence of genes encoding aminoglycoside-modifying enzymes) were also resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    . No isolates in this study were resistant to penicillin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , teicoplanin, or high-level",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , though others have reported high-level resistance to gentamicin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/31,68\">",
"     31,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Resistance to other agents including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    has also been reported (40 to 97 percent and 50 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/25,69\">",
"     25,69",
"    </a>",
"    ]. S. bovis is also relatively resistant to the older fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ); 23 and 54 percent of isolates were resistant in two series [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/25,70\">",
"     25,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transfer of resistance has been demonstrated in the absence of detectable plasmids and has been attributed to chromosomal resistance markers on conjugative transposon-like elements [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/71\">",
"     71",
"    </a>",
"    ]. Genomic analysis of an isolate of S. gallolyticus subspecies gallolyticus that caused IE demonstrated a mobilizable plasmid conferring",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comparisons between susceptibility reports may be difficult due to variation in geography, collection methods, and typing. There are limited data on species-level susceptibility and subspecies-level differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/27,73,74\">",
"     27,73,74",
"    </a>",
"    ]. The various species and subspecies of the S. bovis group generally display similar susceptibility profiles, with susceptibility to penicillins and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    and higher rates of resistance to non-beta-lactam agents [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/27,75\">",
"     27,75",
"    </a>",
"    ]. In some series, S. infantarius (biotype",
"    <span class=\"nowrap\">",
"     II/1)",
"    </span>",
"    showed demonstrated susceptibility to non-beta-lactam agents than other S. bovis species [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/27,74\">",
"     27,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1612075375\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of S. bovis infection is based upon susceptibility data and clinical trials that usually include patients with endocarditis or bacteremia caused by a number of streptococcal species. The approach to treatment is based on a number of factors including antibiotic susceptibility, the presence of prosthetic heart valves or other endovascular material, cardiac complications, evidence of distant septic foci, response to therapy, and individual patient circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/61,76\">",
"     61,76",
"    </a>",
"    ]. Drugs of choice for systemic S. bovis infection include penicillin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is the preferred agent for patients with serious allergy to both penicillin and ceftriaxone.",
"   </p>",
"   <p>",
"    Tetracyclines,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , macrolides, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    may not be active against S. bovis and are not appropriate for treatment of endocarditis. Although newer fluoroquinolones have enhanced in vitro gram-positive activity (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ), these agents are generally not appropriate for treatment of bacteremia or other invasive infections due to S. bovis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     Daptomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    are highly active against S. bovis. Of these, daptomycin may be useful for treatment of S. bovis bacteremia and endocarditis in the unusual patient who is unable to tolerate beta-lactams or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1612075381\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to S. bovis endocarditis discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link&amp;anchor=H8#H8\">",
"     \"Antimicrobial therapy of native valve endocarditis\", section on 'Viridans streptococci and Streptococcus bovis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link&amp;anchor=H6#H6\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\", section on 'Streptococci'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1612075387\">",
"    <span class=\"h3\">",
"     For MIC &lt;0.5",
"    </span>",
"    &nbsp;&mdash;&nbsp;Issues related to treatment of native valve endocarditis due to S. bovis isolates with minimum inhibitory concentration (MIC) of penicillin MIC &lt;0.125 and penicillin MIC &ge;0.125 but &lt;0.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    are summarized in tables and discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef73007 \" href=\"UTD.htm?6/53/7006\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef53990 \" href=\"UTD.htm?22/16/22797\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link&amp;anchor=H8#H8\">",
"     \"Antimicrobial therapy of native valve endocarditis\", section on 'Viridans streptococci and Streptococcus bovis'",
"    </a>",
"    .)",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    In an early series including 13 patients with S. bovis endocarditis (MIC &le;0.12",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    who received treatment with penicillin alone or combined with &le;4 days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , all but one survived [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/32\">",
"     32",
"    </a>",
"    ]. For treatment of infection due to S. bovis that is not fully susceptible to penicillin (MIC &gt;0.1",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    published clinical data are limited; treatment regimens are extrapolated from those used to treat viridans streptococcal endocarditis.",
"   </p>",
"   <p>",
"    Short-course (two weeks versus standard four weeks) treatment regimens with once-daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    plus once-daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or netilmicin have been successful in patients with uncomplicated, penicillin-susceptible streptococcal IE [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. In one study including 18 cases of S. bovis endocarditis, no bacteriologic failures were observed (although there was no control group) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1612075392\">",
"    <span class=\"h3\">",
"     For MIC &ge;0.5",
"    </span>",
"    &nbsp;&mdash;&nbsp;Native valve endocarditis due to S. bovis isolates with MIC &ge;0.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    is managed as infection due to susceptible enterococcus strains. Treatment is summarized in the table and discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef50418 \" href=\"UTD.htm?30/24/31117\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link&amp;anchor=H11#H11\">",
"     \"Antimicrobial therapy of native valve endocarditis\", section on 'Enterococci'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1612075398\">",
"    <span class=\"h2\">",
"     Bacteremia and other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of S. bovis infection in the absence of endocarditis is uncertain, as data are limited. Patients with S. bovis bacteremia and meningitis have responded to high-dose penicillin for &ge;2 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/42\">",
"     42",
"    </a>",
"    ], and similarly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    is likely active.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1612075403\">",
"    <span class=\"h2\">",
"     Colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the pronounced association between S. bovis infection and colonic neoplasia, all adults with S. bovis infection should undergo colonoscopy. The association between S. bovis and colonic neoplasm is strongest for S. gallolyticus subspecies gallolyticus and for IE cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/19\">",
"     19",
"    </a>",
"    ]. If negative, colonoscopy should be repeated in four to six months. Evaluation for liver disease and extracolonic malignancy may also be warranted depending on individual circumstances [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22041/abstract/25,80\">",
"     25,80",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24506924\">",
"     'Association with colonic neoplasia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1612075409\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Streptococcus bovis is an important cause of bacteremia and infective endocarditis (IE) in adults. It accounts for 2 to 6 percent of streptococcal bloodstream isolates from hospitalized patients and 6 percent of endocarditis cases worldwide. The gastrointestinal tract is the most likely portal of entry, and S. bovis infection is associated with colonic neoplasia. S. gallolyticus subspecies gallolyticus (S. bovis biotype I) has the strongest association with IE and with colonic neoplasia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of infection due to S. bovis is made via the isolation of the organism from blood, other body fluid, or tissue. Gram positive cocci that grow on agar in the presence of 40 percent bile and which hydrolyze esculin are very likely to be group D streptococci or enterococci. S. bovis fails to grow in 6.5 percent NaCl broth, cannot hydrolyze arginine, and is PYR (pyrrolidonyl arylamidase) negative, which assists in distinguishing it from enterococci. Additional biochemical tests, commercial kits, and automated testing can distinguish S. bovis from viridans streptococci and can discriminate within the S. bovis group to the subspecies level. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      S. bovis is substantially more susceptible to penicillin and other beta-lactam antibiotics than enterococci. S. bovis resistance to non beta-lactam antibiotic classes is relatively common. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Antibiotic resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Issues related to treatment of native valve endocarditis due to S. bovis isolates with minimum inhibitory concentration (MIC) &lt;0.5",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      are summarized in tables and discussed in detail separately (",
"      <a class=\"graphic graphic_table graphicRef73007 \" href=\"UTD.htm?6/53/7006\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53990 \" href=\"UTD.htm?22/16/22797\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1612075381\">",
"       'Endocarditis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link&amp;anchor=H8#H8\">",
"       \"Antimicrobial therapy of native valve endocarditis\", section on 'Viridans streptococci and Streptococcus bovis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Native valve endocarditis due to S. bovis isolates with MIC &ge;0.5",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      is managed as infection due to susceptible enterococcus strains. Treatment is summarized in the Table and discussed in detail separately (",
"      <a class=\"graphic graphic_table graphicRef50418 \" href=\"UTD.htm?30/24/31117\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1612075381\">",
"       'Endocarditis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link&amp;anchor=H11#H11\">",
"       \"Antimicrobial therapy of native valve endocarditis\", section on 'Enterococci'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For treatment of penicillin-susceptible S. bovis infection in the absence of endocarditis, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (1 to 2 g once daily for most infections, 2 g twice a day for meningitis) or penicillin (12 to 24 million units IV daily, divided every four hours) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ); the appropriate duration is at least two weeks. (See",
"      <a class=\"local\" href=\"#H1612075398\">",
"       'Bacteremia and other infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that all adults with S. bovis bacteremia undergo colonoscopy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). If negative, colonoscopy should be repeated in four to six months. Evaluation for liver disease and extracolonic malignancy may also be warranted depending on individual circumstances. (See",
"      <a class=\"local\" href=\"#H24506924\">",
"       'Association with colonic neoplasia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1612075403\">",
"       'Colonoscopy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/1\">",
"      Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis 2011; 53:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/2\">",
"      Corredoira JC, Alonso MP, Garc&iacute;a JF, et al. Clinical characteristics and significance of Streptococcus salivarius bacteremia and Streptococcus bovis bacteremia: a prospective 16-year study. Eur J Clin Microbiol Infect Dis 2005; 24:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/3\">",
"      Schlegel L, Grimont F, Ageron E, et al. Reappraisal of the taxonomy of the Streptococcus bovis/Streptococcus equinus complex and related species: description of Streptococcus gallolyticus subsp. gallolyticus subsp. nov., S. gallolyticus subsp. macedonicus subsp. nov. and S. gallolyticus subsp. pasteurianus subsp. nov. Int J Syst Evol Microbiol 2003; 53:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/4\">",
"      Facklam R. What happened to the streptococci: overview of taxonomic and nomenclature changes. Clin Microbiol Rev 2002; 15:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/5\">",
"      van't Wout JW, Bijlmer HA. Bacteremia due to Streptococcus gallolyticus, or the perils of revised nomenclature in bacteriology. Clin Infect Dis 2005; 40:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/6\">",
"      Ruoff KL, Miller SI, Garner CV, et al. Bacteremia with Streptococcus bovis and Streptococcus salivarius: clinical correlates of more accurate identification of isolates. J Clin Microbiol 1989; 27:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/7\">",
"      Fern&aacute;ndez-Ruiz M, Villar-Silva J, Llenas-Garc&iacute;a J, et al. Streptococcus bovis bacteraemia revisited: clinical and microbiological correlates in a contemporary series of 59 patients. J Infect 2010; 61:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/8\">",
"      Pfaller MA, Jones RN, Marshall SA, et al. Nosocomial streptococcal blood stream infections in the SCOPE Program: species occurrence and antimicrobial resistance. The SCOPE Hospital Study Group. Diagn Microbiol Infect Dis 1997; 29:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/9\">",
"      Eggers S, Beuth J. Etiology and antibiotic susceptibility of bloodstream Streptococcus sp. Zentralbl Bakteriol 1992; 276:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/10\">",
"      Murray HW, Roberts RB. Streptococcus bovis bacteremia and underlying gastrointestinal disease. Arch Intern Med 1978; 138:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/11\">",
"      Zarkin BA, Lillemoe KD, Cameron JL, et al. The triad of Streptococcus bovis bacteremia, colonic pathology, and liver disease. Ann Surg 1990; 211:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/12\">",
"      Corredoira J, Alonso MP, Coira A, et al. Characteristics of Streptococcus bovis endocarditis and its differences with Streptococcus viridans endocarditis. Eur J Clin Microbiol Infect Dis 2008; 27:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/13\">",
"      Murdoch DR, Corey GR, Hoen B, et al. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009; 169:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/14\">",
"      Panwalker AP. Unusual infections associated with colorectal cancer. Rev Infect Dis 1988; 10:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/15\">",
"      Klein RS, Recco RA, Catalano MT, et al. Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med 1977; 297:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/16\">",
"      Klein RS, Catalano MT, Edberg SC, et al. Streptococcus bovis septicemia and carcinoma of the colon. Ann Intern Med 1979; 91:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/17\">",
"      Potter MA, Cunliffe NA, Smith M, et al. A prospective controlled study of the association of Streptococcus bovis with colorectal carcinoma. J Clin Pathol 1998; 51:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/18\">",
"      Ballet M, Gevigney G, Gar&eacute; JP, et al. Infective endocarditis due to Streptococcus bovis. A report of 53 cases. Eur Heart J 1995; 16:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/19\">",
"      Alazmi W, Bustamante M, O'Loughlin C, et al. The association of Streptococcus bovis bacteremia and gastrointestinal diseases: a retrospective analysis. Dig Dis Sci 2006; 51:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/20\">",
"      Leport C, Bure A, Leport J, Vilde JL. Incidence of colonic lesions in Streptococcus bovis and enterococcal endocarditis. Lancet 1987; 1:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/21\">",
"      Corredoira-S&aacute;nchez J, Garc&iacute;a-Garrote F, Rabu&ntilde;al R, et al. Association between bacteremia due to Streptococcus gallolyticus subsp. gallolyticus (Streptococcus bovis I) and colorectal neoplasia: a case-control study. Clin Infect Dis 2012; 55:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/22\">",
"      Burns CA, McCaughey R, Lauter CB. The association of Streptococcus bovis fecal carriage and colon neoplasia: possible relationship with polyps and their premalignant potential. Am J Gastroenterol 1985; 80:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/23\">",
"      Moshkowitz M, Arber N, Wajsman R, et al. Streptococcus bovis endocarditis as a presenting manifestation of idiopathic ulcerative colitis. Postgrad Med J 1992; 68:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/24\">",
"      Boleij A, Schaeps RM, Tjalsma H. Association between Streptococcus bovis and colon cancer. J Clin Microbiol 2009; 47:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/25\">",
"      Tripodi MF, Adinolfi LE, Ragone E, et al. Streptococcus bovis endocarditis and its association with chronic liver disease: an underestimated risk factor. Clin Infect Dis 2004; 38:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/26\">",
"      Lee RA, Woo PC, To AP, et al. Geographical difference of disease association in Streptococcus bovis bacteraemia. J Med Microbiol 2003; 52:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/27\">",
"      Beck M, Frodl R, Funke G. Comprehensive study of strains previously designated Streptococcus bovis consecutively isolated from human blood cultures and emended description of Streptococcus gallolyticus and Streptococcus infantarius subsp. coli. J Clin Microbiol 2008; 46:2966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/28\">",
"      Hoen B, Chirouze C, Cabell CH, et al. Emergence of endocarditis due to group D streptococci: findings derived from the merged database of the International Collaboration on Endocarditis. Eur J Clin Microbiol Infect Dis 2005; 24:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/29\">",
"      Ravreby WD, Bottone EJ, Keusch GT. Group D streptococcal bacteremia, with emphasis on the incidence and presentation of infectious due to Streptococcus bovis. N Engl J Med 1973; 289:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/30\">",
"      Kupferwasser I, Darius H, M&uuml;ller AM, et al. Clinical and morphological characteristics in Streptococcus bovis endocarditis: a comparison with other causative microorganisms in 177 cases. Heart 1998; 80:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/31\">",
"      Duval X, Papastamopoulos V, Longuet P, et al. Definite streptococcus bovis endocarditis: characteristics in 20 patients. Clin Microbiol Infect 2001; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/32\">",
"      Moellering RC Jr, Watson BK, Kunz LJ. Endocarditis due to group D streptococci. Comparison of disease caused by streptococcus bovis with that produced by the enterococci. Am J Med 1974; 57:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/33\">",
"      Bassetti M, Secchi G, Borziani S, et al. Successful treatment of four-valve native endocarditis caused by Streptococcus bovis. Int J Cardiol 2004; 97:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/34\">",
"      Pergola V, Di Salvo G, Habib G, et al. Comparison of clinical and echocardiographic characteristics of Streptococcus bovis endocarditis with that caused by other pathogens. Am J Cardiol 2001; 88:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/35\">",
"      Hoen B, Alla F, Selton-Suty C, et al. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA 2002; 288:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/36\">",
"      Gonzlez-Quintela A, Mart&iacute;nez-Rey C, Castroagud&iacute;n JF, et al. Prevalence of liver disease in patients with Streptococcus bovis bacteraemia. J Infect 2001; 42:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/37\">",
"      Gergaud JM, Breux JP, Roblot P, et al. [Neurologic complications of infectious endocarditis]. Ann Med Interne (Paris) 1995; 146:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/38\">",
"      Chang AH, Kirsch CM, Mobashery N, et al. Streptococcus bovis septic shock due to contaminated transfused platelets. Am J Hematol 2004; 77:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/39\">",
"      Gavin PJ, Thomson RB Jr, Horng SJ, Yogev R. Neonatal sepsis caused by Streptococcus bovis variant (biotype II/2): report of a case and review. J Clin Microbiol 2003; 41:3433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/40\">",
"      Cheung M, Pelot M, Nadarajah R, Kohl S. Neonate with late onset Streptococcus bovis meningitis: case report and review of the literature. Pediatr Infect Dis J 2000; 19:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/41\">",
"      Klatte JM, Clarridge JE 3rd, Bratcher D, Selvarangan R. A longitudinal case series description of meningitis due to Streptococcus gallolyticus subsp. pasteurianus in infants. J Clin Microbiol 2012; 50:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/42\">",
"      Cohen LF, Dunbar SA, Sirbasku DM, Clarridge JE 3rd. Streptococcus bovis infection of the central nervous system: report of two cases and review. Clin Infect Dis 1997; 25:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/43\">",
"      Jain AK, Agarwal SK, el-Sadr W. Streptococcus bovis bacteremia and meningitis associated with Strongyloides stercoralis colitis in a patient infected with human immunodeficiency virus. Clin Infect Dis 1994; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/44\">",
"      Coret Ferrer F, Vilchez Padilla JJ, Igual Adell R, Ferrando Ginestar J. Streptococcus bovis meningitis: no association with colonic malignancy. Clin Infect Dis 1993; 17:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/45\">",
"      Leibovitch G, Maaravi Y, Shalev O. Multiple brain abscesses caused by Streptococcus bovis. J Infect 1991; 23:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/46\">",
"      Maniglia RJ, Roth T, Blumberg EA. Polymicrobial brain abscess in a patient infected with human immunodeficiency virus. Clin Infect Dis 1997; 24:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/47\">",
"      Grant RJ, Shang WY, Whitehead TR. Isolated septic arthritis due to Streptococcus bovis. Clin Infect Dis 1997; 24:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/48\">",
"      Emerton ME, Crook DW, Cooke PH. Streptococcus bovis-infected total hip arthroplasty. J Arthroplasty 1995; 10:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/49\">",
"      Bajwa ZH, Ho C, Grush A, et al. Discitis associated with pregnancy and spinal anesthesia. Anesth Analg 2002; 94:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/50\">",
"      Bleibel W, D'Silva K, Elhorr A, et al. Streptococcus bovis endophthalmitis: a unique presentation of colon cancer. Dig Dis Sci 2007; 52:2336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/51\">",
"      Goumas PD, Naxakis SS, Rentzis GA, et al. Lateral neck abscess caused by Streptococcus bovis in a patient with undiagnosed colon cancer. J Laryngol Otol 1997; 111:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/52\">",
"      Ackerman Z, Eliakim R, Stalnikowicz R. Spontaneous peritonitis caused by Streptococcus bovis: search for colonic neoplasia. J Clin Gastroenterol 1995; 21:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/53\">",
"      Wong SS, Woo PC, Ho PL, Wang TK. Continuous ambulatory peritoneal dialysis-related peritonitis caused by Streptococcus bovis. Eur J Clin Microbiol Infect Dis 2003; 22:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/54\">",
"      Eledrisi MS, Zuckerman MJ, Ho H. Spontaneous bacterial peritonitis caused by Streptococcus bovis. Am J Gastroenterol 2000; 95:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/55\">",
"      Genuth L. Re: Shad and Schindler's report on spontaneous peritonitis due to Streptococcus bovis. Am J Gastroenterol 2000; 95:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/56\">",
"      Chuard C, Reller LB. Bile-esculin test for presumptive identification of enterococci and streptococci: effects of bile concentration, inoculation technique, and incubation time. J Clin Microbiol 1998; 36:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/57\">",
"      Clarridge JE 3rd, Attorri SM, Zhang Q, Bartell J. 16S ribosomal DNA sequence analysis distinguishes biotypes of Streptococcus bovis: Streptococcus bovis Biotype II/2 is a separate genospecies and the predominant clinical isolate in adult males. J Clin Microbiol 2001; 39:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/58\">",
"      Haanper&auml; M, Jalava J, Huovinen P, et al. Identification of alpha-hemolytic streptococci by pyrosequencing the 16S rRNA gene and by use of VITEK 2. J Clin Microbiol 2007; 45:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/59\">",
"      Mouton JW, Endtz HP, den Hollander JG, et al. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis. J Antimicrob Chemother 1997; 39 Suppl A:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/60\">",
"      Matsumura M, Araki T, Yokogawa A. Streptococcus bovis discitis and possible endocarditis. Intern Med 2000; 39:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/61\">",
"      Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/62\">",
"      Thornsberry C, Baker CN, Facklam RR. Antibiotic susceptibility of Streptococcus bovis and other group D streptococci causing endocarditis. Antimicrob Agents Chemother 1974; 5:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/63\">",
"      Fung JC, Gadbaw JJ Jr, Donta ST, Tilton RC. Infective endocarditis due to penicillin-tolerant Streptococcus bovis. Diagn Microbiol Infect Dis 1986; 5:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/64\">",
"      Venditti M, Gelfusa V, Serra P, et al. 4-week treatment of streptococcal native valve endocarditis with high-dose teicoplanin. Antimicrob Agents Chemother 1992; 36:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/65\">",
"      Leclercq R, Huet C, Picherot M, et al. Genetic basis of antibiotic resistance in clinical isolates of Streptococcus gallolyticus (Streptococcus bovis). Antimicrob Agents Chemother 2005; 49:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/66\">",
"      Rodr&iacute;guez-Avial I, Rodr&iacute;guez-Avial C, Culebras E, Picazo JJ. In vitro activity of telithromycin against viridans group streptococci and Streptococcus bovis isolated from blood: antimicrobial susceptibility patterns in different groups of species. Antimicrob Agents Chemother 2005; 49:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/67\">",
"      Streit JM, Steenbergen JN, Thorne GM, et al. Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. J Antimicrob Chemother 2005; 55:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/68\">",
"      Kaufhold A, Potgieter E. Chromosomally mediated high-level gentamicin resistance in Streptococcus mitis. Antimicrob Agents Chemother 1993; 37:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/69\">",
"      Teng LJ, Hsueh PR, Ho SW, Luh KT. High prevalence of inducible erythromycin resistance among Streptococcus bovis isolates in Taiwan. Antimicrob Agents Chemother 2001; 45:3362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/70\">",
"      Kerawala M, Ambler JE, Lee PY, Drabu YJ. In vitro activity of gemifloxacin (SB-265805) compared to eleven other antimicrobial agents against streptococcal isolates, excluding Streptococcus pneumoniae. Eur J Clin Microbiol Infect Dis 2001; 20:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/71\">",
"      David F, de C&eacute;sp&egrave;des G, Delbos F, Horaud T. Diversity of chromosomal genetic elements and gene identification in antibiotic-resistant strains of Streptococcus pneumoniae and Streptococcus bovis. Plasmid 1993; 29:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/72\">",
"      Hinse D, Vollmer T, R&uuml;ckert C, et al. Complete genome and comparative analysis of Streptococcus gallolyticus subsp. gallolyticus, an emerging pathogen of infective endocarditis. BMC Genomics 2011; 12:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/73\">",
"      Moet GJ, Dowzicky MJ, Jones RN. Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci. Diagn Microbiol Infect Dis 2007; 57:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/74\">",
"      Romero B, Morosini MI, Loza E, et al. Reidentification of Streptococcus bovis isolates causing bacteremia according to the new taxonomy criteria: still an issue? J Clin Microbiol 2011; 49:3228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/75\">",
"      Tripodi MF, Fortunato R, Utili R, et al. Molecular epidemiology of Streptococcus bovis causing endocarditis and bacteraemia in Italian patients. Clin Microbiol Infect 2005; 11:814.",
"     </a>",
"    </li>",
"    <li>",
"     Roberts RB. Streptococcal endocarditis: The viridans and beta hemolytic streptococci. In: Infective Endocarditis, Kaye D (Ed), Raven Press, New York 1992. p.191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/77\">",
"      Hoogkamp-Korstanje JA, Roelofs-Willemse J. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates. J Antimicrob Chemother 2000; 45:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/78\">",
"      Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 1995; 21:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/79\">",
"      Sexton DJ, Tenenbaum MJ, Wilson WR, et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis 1998; 27:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22041/abstract/80\">",
"      Gold JS, Bayar S, Salem RR. Association of Streptococcus bovis bacteremia with colonic neoplasia and extracolonic malignancy. Arch Surg 2004; 139:760.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3156 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22041=[""].join("\n");
var outline_f21_33_22041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1612075409\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24505889\">",
"      CLINICAL ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24505897\">",
"      Association with endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24506924\">",
"      Association with colonic neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24506986\">",
"      Association with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1612075351\">",
"      Bacteremia and endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Other sites of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ANTIBIOTIC RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1612075375\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1612075381\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1612075387\">",
"      - For MIC &lt;0.5",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1612075392\">",
"      - For MIC &ge;0.5",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1612075398\">",
"      Bacteremia and other infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1612075403\">",
"      Colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1612075409\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3156\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3156|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/9/42140\" title=\"table 1A\">",
"      Strep bovis susceptibilities I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/18/12589\" title=\"table 1B\">",
"      Strep bovis susceptibilities II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/53/7006\" title=\"table 2\">",
"      Rx strep endocarditis I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/16/22797\" title=\"table 3\">",
"      Rx strep endocarditis II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/24/31117\" title=\"table 4\">",
"      Rx entero endocarditis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29926?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of Streptococcus bovis infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_33_22042="Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer";
var content_f21_33_22042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22042/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22042/contributors\">",
"     David P Ryan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22042/contributors\">",
"     Harvey Mamon, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22042/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22042/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22042/contributors\">",
"     Christopher G Willett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/33/22042/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/33/22042/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/33/22042/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 45,000 people develop exocrine pancreatic cancer each year in the United States, and almost all are expected to die from the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of these tumors (85 percent) are adenocarcinomas arising from the ductal epithelium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=see_link\">",
"     \"Pathology of exocrine pancreatic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical resection offers the only chance of cure, but only 15 to 20 percent of cases are potentially resectable at presentation. Furthermore, prognosis is poor, even for those undergoing complete (R0) resection. Reported five-year survival rates following pancreaticoduodenectomy for node-negative and node-positive disease are 25 to 30, and 10 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/2-6\">",
"     2-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcomes may be improving over time, possibly related to an increase in the proportion of patients undergoing surgery at teaching hospitals, lower perioperative mortality rates, better patient selection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    greater use of adjuvant therapy. As an example, in a report of 396 Medicare patients residing in one of 11 SEER (Surveillance, Epidemiology and End Results) registries who underwent curative intent surgery for pancreatic cancer between 1991 and 1996, the three-year survival rate was 34 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/7\">",
"     7",
"    </a>",
"    ]. In multivariate analysis, one of the strongest predictors for survival was the use of adjuvant chemoradiotherapy; the three year survival rate was significantly higher among those who received it compared to those who did not (45 versus 30 percent, respectively).",
"   </p>",
"   <p>",
"    Nevertheless, these patients still have a relatively poor prognosis overall. Systemic chemotherapy, radiation therapy (RT), or a combination of both modalities (chemoradiotherapy) have been used following surgical resection (adjuvant therapy) and even prior to resection (neoadjuvant therapy) in an effort to improve cure rates. Although the benefit of adjuvant therapy has become more apparent in recent years, the optimal choice of treatment modality (chemotherapy with or without RT) remains intensely controversial.",
"   </p>",
"   <p>",
"    Adjuvant and neoadjuvant therapies for exocrine pancreatic cancer will be reviewed here. Surgical management of localized exocrine pancreatic cancer, treatment of locally advanced tumors, and chemotherapy for advanced disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=see_link\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=see_link\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33370?source=see_link\">",
"     \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39114?source=see_link\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPY FOR PANCREATIC CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy, RT or a combination of chemotherapy and RT have all been applied following surgery in an effort to improve outcome in patients undergoing potentially curative (R0) resection. The rationale for combined modality therapy is provided by the failure pattern following surgical resection alone. In an autopsy series of 76 patients who had been treated for pancreatic cancer, 15 percent of those who had surgery alone for stage I or II disease had a local recurrence in the pancreatic bed alone, while 65 percent had both locally recurrent and metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/8\">",
"     8",
"    </a>",
"    ]. The local control benefit of adding radiotherapy can be best illustrated by data from the GERCOR trial of postoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    versus gemcitabine-based chemoradiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/9\">",
"     9",
"    </a>",
"    ]. The rate of local recurrence alone at first progression in the chemoradiotherapy group was notably lower (11 versus 24 percent) as was the rate of simultaneous local and distant progression (13 versus 20 percent); in contrast, the rates of distant progression were similar (40 versus 42 percent). (See",
"    <a class=\"local\" href=\"#H698255022\">",
"     'Chemotherapy versus chemoradiotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An important point is that over the last 25 years, three major trends have impacted our ability to evaluate the effectiveness of various therapies and makes the comparison of studies across this time period very difficult.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The definition of an R0 (complete) resection has evolved dramatically. While it was previously thought that only the pancreatic transection margins were important in determining the completeness of the resection, it is now clear that the retroperitoneal margin is the most frequently positive margin and that the presence of a positive retroperitoneal margin is associated with a very poor prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/6,10-12\">",
"       6,10-12",
"      </a>",
"      ]. Nevertheless, many recent studies include a large proportion of patients with positive retroperitoneal margins, and it must be assumed that many of the patients in the older studies had a positive retroperitoneal margin, although this was usually not stated.",
"     </li>",
"     <li>",
"      Radiation techniques have changed over the last 25 years. Among the most important changes are the abandonment of split course radiation, an acknowledgment that the optimal dose is 50.4 to 54 Gy for upper gastrointestinal cancers, and the use of CT planning to better define the radiation boundaries.",
"     </li>",
"     <li>",
"      It is now recognized that the skills of both the surgeon and the institution caring for the patient affect outcome dramatically (both in the short run and in the long-term). As an example, using volume as a surrogate for skill, one study showed that mortality rates following a Whipple procedure for a low-volume (fewer than two procedures per year), intermediate-volume (two to four per year), or high-volume (greater than four a year) surgeon in the late 1990s were 14.7, 8.5 and 4.6 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/13\">",
"       13",
"      </a>",
"      ]. Hospital volume was also an independent predictor of mortality. Notably, 65 percent of the Whipple procedures were performed by surgeons who did four or fewer each year. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=see_link&amp;anchor=H7#H7\">",
"       \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Perioperative morbidity and mortality'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gastrointestinal Tumor Study Group (GITSG) initially demonstrated improved survival when external beam RT was combined with concurrent 5-fluorouracil (5-FU) chemotherapy compared to RT alone in patients with locally advanced unresectable pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. This combined modality regimen was subsequently applied to patients who had undergone an R0 resection in an attempt to improve the surgical cure rate. However, despite the publication of several randomized trials evaluating postoperative chemoradiotherapy or a combination of preoperative plus postoperative combined modality therapy in patients with resected pancreatic cancer, its true benefit remains controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     GITSG study",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a study conducted in the late 1970s and early 1980s by GITSG, patients were randomly assigned to either observation or external beam RT (EBRT, 40 Gy) plus concurrent bolus 5-FU (500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day on the first three and last three days of RT), followed by maintenance chemotherapy (5-FU 500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for three days monthly) for two years or until disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/16\">",
"     16",
"    </a>",
"    ]. The study was terminated after eight years due to poor patient accrual. As a result, only 43 patients were available for analysis.",
"   </p>",
"   <p>",
"    Despite the relatively low RT dose, small number of patients, and the fact that 25 percent of the patients on the treatment arm did not begin postoperative treatment until more than 10 weeks following resection, patients receiving postoperative chemoradiotherapy had significantly longer median overall survival (20 versus 11 months) and a doubling of the two-year survival rate (20 versus 10 percent). Following closure of the study, an additional 32 patients were registered on the combined modality arm, and a subsequent report that included these and the original 43 patients confirmed the initial survival benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     EORTC study",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to reproduce these findings, a study sponsored by the European Organization for Research and Treatment of Cancer (EORTC) randomly assigned 114 patients with resected pancreatic cancer to postoperative concurrent 5-FU (25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day by continuous infusion) plus EBRT (40 Gy in split courses) or observation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/18\">",
"     18",
"    </a>",
"    ]. In contrast to the GITSG findings, postoperative chemoradiotherapy did not significantly improve median overall survival or two-year survival (26 versus 34 percent for control and treated patients, respectively, p = 0.099).",
"   </p>",
"   <p>",
"    However, like the GITSG trial, this study was also criticized for several reasons: RT was delivered in a split-course manner (potentially allowing for tumor repopulation between courses), the dose was suboptimal, and there was no prospective assessment of the completeness of surgical margins. Furthermore, 20 percent of patients randomized to treatment never received it. However, since the trial did show a trend towards benefit of adjuvant therapy and was considered underpowered, some investigators viewed this study as supporting the conclusions of the GITSG trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     ESPAC-1 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ambitious second trial sponsored by European investigators, the ESPAC-1 trial, initially set out to randomize patients to a 2x2 factorial design in which the relative benefits of adjuvant chemotherapy, chemoradiotherapy, or chemoradiotherapy followed by chemotherapy would be compared to observation alone. However, fear of poor accrual led the investigators to permit physicians to choose from this or two other randomization schemes (described below). The final results were presented in two separate publications, one that pooled the results from the three parallel randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/19\">",
"     19",
"    </a>",
"    ] and a later report that focused on the 289 patients randomized to the four-arm study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pooled analysis included 541 patients (including those with positive margins) who were randomly assigned to postoperative treatment following resection of exocrine pancreatic cancer in the following three parallel studies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemoradiotherapy versus no chemoradiotherapy &mdash; 68 patients enrolled; chemoradiotherapy consisted of 20 Gy EBRT plus three days of concomitant 5-FU, repeated after a planned break of two weeks.",
"     </li>",
"     <li>",
"      Adjuvant chemotherapy versus no chemotherapy &mdash;188 patients enrolled; adjuvant chemotherapy consisted of bolus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      -modulated 5-FU (leucovorin 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      5-FU 425",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ),",
"      </span>",
"      administered daily for five days, every 28 days, for six months.",
"     </li>",
"     <li>",
"      A 2x2 factorial design trial with four groups: chemoradiotherapy (n = 73), chemotherapy (n = 75), both (n = 72), or observation (n = 69) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/20\">",
"       20",
"      </a>",
"      ]; the chemoradiotherapy and chemotherapy treatments were as described above. The number of patients needed per arm was based upon finding a 20 percent improvement in mortality rate at two years when the groups receiving chemoradiotherapy versus no chemoradiotherapy, and chemotherapy versus no chemotherapy were compared.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the initial report of the pooled analysis, there was no survival difference when the 175 patients receiving postoperative chemoradiotherapy were compared to the 178 who did not receive it (median overall survival 15.5 versus 16.1 months, respectively). In contrast, there was a significant survival benefit for adjuvant chemotherapy alone when 238 patients who received it were compared to 235 who did not receive it (median survival 19.7 versus 14 months, respectively).",
"   </p>",
"   <p>",
"    This analysis was criticized for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients and clinicians were allowed to select which trial to enter, raising concerns as to generalizability and the appropriateness of combining results.",
"     </li>",
"     <li>",
"      Clinicians were allowed, according to their own preferences, to deliver \"background\" chemoradiation or chemotherapy.",
"     </li>",
"     <li>",
"      Comparisons of treatment groups that were pooled together by treatment actually received, rather than \"intent-to-treat\" analysis, resulted in nearly one-third of the \"no chemotherapy\" and \"chemotherapy alone\" patients receiving chemoradiotherapy.",
"     </li>",
"     <li>",
"      Similar to the EORTC trial discussed above, the chemoradiotherapy group received RT in a split course fashion, and the final dose (ranging from 40 to 60 Gy) was left to the judgment of the treating physician.",
"     </li>",
"     <li>",
"      The chemoradiotherapy group did not include postradiotherapy adjuvant chemotherapy; thus, the results cannot be directly compared to the results of the GITSG trial.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some (but not all) of these concerns were addressed in a subsequent report that included only the 289 patients randomized to the four arm study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/20\">",
"     20",
"    </a>",
"    ]. In an intent-to-treat analysis, there was no significant benefit for chemoradiotherapy in the two groups that received it, and in fact, the data suggested a trend toward worse survival for this group (two and five-year survival rates were 29 versus 41 percent, and 10 versus 20 percent for the chemoradiotherapy and no chemoradiotherapy groups, respectively). There were no significant imbalances for known prognostic factors (nodal positivity, resection margin status, histologic grade) in the two arms that could have contributed to these results. Local recurrence rates were similar in both groups, but there were more recurrences overall (84 versus 74) in the chemoradiotherapy group and a shorter recurrence-free interval (10.7 versus 15.2 months, respectively).",
"   </p>",
"   <p>",
"    In contrast to these results, both the two-year (40 versus 30 percent) and five-year (21 versus 8 percent) survival rates were significantly greater among patients randomized to postoperative chemotherapy alone compared to those who did not receive it, despite the fact that 33 percent of those assigned to adjuvant chemotherapy did not complete all six courses, and 17 percent received no chemotherapy at all. The median survival for patients treated with chemotherapy versus no chemotherapy was 20.1 versus 15.5 months, respectively.",
"   </p>",
"   <p>",
"    The authors postulated that the delay in the administration of systemic chemotherapy in patients undergoing chemoradiotherapy might explain the inferior outcomes seen in this group. Although the trial was underpowered to perform statistical comparisons of the four individual treatment groups, patients in both chemoradiotherapy groups had an inferior median overall survival (13.9 and 14.2 months for chemoradiotherapy alone or chemoradiotherapy plus chemotherapy) as compared to those undergoing observation alone (16.9 months). These median survival durations are markedly lower than those seen in other contemporary series of patients treated with adjuvant chemoradiotherapy (21 to 25 months in several reports [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]), and suggest that treatment-related toxicity might have accounted for some of the differences.",
"   </p>",
"   <p>",
"    In summary, it is difficult to draw firm conclusions regarding the benefit of chemoradiotherapy from the ESPAC-1 trial. Although there are no large contemporary randomized trials that confirm the GITSG data, it should be noted that in other gastrointestinal cancers where local failure is a common problem (eg, gastric and rectal cancer), a survival benefit has been shown in large randomized trials for patients receiving a combination of adjuvant chemoradiation and chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Uncontrolled series",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other investigators have reported retrospective data that suggest benefit for postoperative chemoradiotherapy in pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/7,21,23-31\">",
"     7,21,23-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest of these series included 1092 patients who underwent pancreaticoduodenectomy followed by either observation or 5-FU-based chemoradiotherapy at the Johns Hopkins Hospital or the Mayo Clinic between 1985 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients were excluded if they had T4 or M1 disease, if they died within 60 days of surgery, or if they had neoadjuvant therapy, or postoperative chemotherapy or RT alone.",
"   </p>",
"   <p>",
"    5-FU-based adjuvant chemoradiotherapy was given to 583 patients; the median daily fraction size and total dose were 1.8 and 50.4 Gy, respectively; the use of postchemoradiotherapy administration of 5-FU monotherapy was not stated. The remaining 345 patients declined any postoperative therapy. Resection margins were positive in one-third of patients, while 68 percent had involved lymph nodes.",
"   </p>",
"   <p>",
"    The median follow-up of the entire cohort was 18.2 months. Compared to no postoperative therapy, postoperative adjuvant chemoradiotherapy was associated with a significantly better survival (median 21.1 versus 15.5 months, two-year survival 45 versus 31 percent; five-year survival 25 versus 12 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Interferon plus 5-FU and cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefit for adjuvant interferon-modulated 5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    with concurrent RT was suggested in a prospective uncontrolled study involving 43 patients who underwent pancreaticoduodenectomy for exocrine pancreatic cancer (84 percent lymph node-positive, 72 percent stage III [(",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"UTD.htm?42/32/43532\">",
"     table 1",
"    </a>",
"    )]) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/32\">",
"     32",
"    </a>",
"    ]. The postoperative regimen consisted of RT (50 to 54 Gy over five weeks) plus concurrent 5-FU (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    continuous infusion daily throughout RT), cisplatin (30",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    bolus weekly, on days 1, 8, 15, 22, and 29), and interferon alfa (3 X 10(6) units subcutaneously daily during RT); this combined modality regimen was followed by two courses of infusional 5-FU alone (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily during weeks 9 to 14 and 17 to 22).",
"   </p>",
"   <p>",
"    The results were striking. At a mean follow-up duration of 32 months, 67 percent of patients remained alive, and the actuarial two-, three-, and five-year survival rates were 64, 64, and 55 percent, respectively. However, toxicity of this regimen was substantial. Seventy percent of patients had moderate to severe treatment-related toxicity (predominantly gastrointestinal), with 42 percent requiring hospitalization at some point.",
"   </p>",
"   <p>",
"    A multicenter confirmatory trial was carried out by the American College of Surgeons Oncology Group (ACOSOG), with a modification in the treatment regimen intended to reduce toxicity. Despite the lower dose of 5-FU (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily during RT) and IFN (3 mU subcutaneously three times weekly during RT), study accrual was terminated after 89 patients were enrolled because of treatment-related toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/33\">",
"     33",
"    </a>",
"    ]. Nevertheless, at 36-month median follow-up, 69 percent of all patients were still alive 18 months from study registration.",
"   </p>",
"   <p>",
"    Unfortunately, a survival benefit for adjuvant interferon-modulated 5-FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    with concurrent RT regimen could not be shown in a multicenter European trial in which 132 patients with",
"    <span class=\"nowrap\">",
"     R0/R1-resected",
"    </span>",
"    pancreatic cancer were randomly assigned to chemoradiotherapy using the full-dose regimen as initially reported by Piccozzi et al [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/32\">",
"     32",
"    </a>",
"    ] or six courses of bolus FU and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    , given on a daily times five, once per month regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/34\">",
"     34",
"    </a>",
"    ]. At a median follow-up of 43 months, there was no survival benefit for",
"    <span class=\"nowrap\">",
"     interferon/FU/cisplatin/RT",
"    </span>",
"    (median survival 26.5 versus 28.5 months with",
"    <span class=\"nowrap\">",
"     FU/leucovorin",
"    </span>",
"    alone). The incidence of grade 3 or 4 toxicity was 85 percent in the combined modality arm (mainly neutropenia and dehydration) compared to 16 percent (mainly diarrhea) with",
"    <span class=\"nowrap\">",
"     FU/leucovorin",
"    </span>",
"    alone. &nbsp;",
"   </p>",
"   <p>",
"    Thus, this regimen cannot be considered standard postoperative approach after resection of pancreatic cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Gemcitabine-based approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary data support the tolerability and favorable short-term outcomes of regimens that use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    as a radiation sensitizer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/9,35-37\">",
"     9,35-37",
"    </a>",
"    ] but no trials have compared this approach to chemoradiotherapy using 5-FU as the radiation sensitizer, at least in the postoperative setting. A randomized phase II trial comparing gemcitabine-based chemoradiotherapy versus gemcitabine alone is discussed below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Neoadjuvant therapy for potentially resectable tumors'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H698255022\">",
"     'Chemotherapy versus chemoradiotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A slightly different approach, adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    monotherapy both before and after concomitant 5-FU-based chemoradiotherapy, was directly compared to 5-FU-based chemoradiotherapy in which 5-FU was given before, during, and after RT in a United States Intergroup study (Radiation Therapy Oncology Group [RTOG] 9704) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients who had undergone gross total resections for T1-4, N0-1 (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"UTD.htm?42/32/43532\">",
"     table 1",
"    </a>",
"    ) exocrine pancreatic cancer and who were taking in at least 1500 calories daily postoperatively were randomly assigned to one of the following two treatment arms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conventional 5-FU-based chemoradiotherapy &mdash; Three weeks of continuous infusion 5-FU (250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily) followed by chemoradiotherapy (50.4 Gy in 1.8 Gy daily fractions for 5.5 weeks with concurrent infusional 5-FU 250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily), and starting three to five weeks later, two-four week courses of continuous infusion 5-FU (250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily, with a two week rest in between courses)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      arm &mdash; Three weekly doses of gemcitabine alone (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week), followed by the same chemoradiotherapy protocol as for the conventional chemoradiotherapy arm, and starting three to five weeks later, three months of single agent gemcitabine (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for three of every four weeks).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the latest update, there were no significant differences in five-year overall or disease-free survival between the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/39\">",
"     39",
"    </a>",
"    ]. The study was sufficiently powered to separately analyze results according to the primary site (head versus",
"    <span class=\"nowrap\">",
"     body/tail).",
"    </span>",
"    Among patients with pancreatic head tumors (n = 388), there was a trend toward better median (20.5 versus 17.1 months) and five-year survival (22 versus 18 percent, p = 0.08) with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -based adjuvant therapy, although neither difference was statistically significant.",
"   </p>",
"   <p>",
"    There were no differences between the two treatments in patients with",
"    <span class=\"nowrap\">",
"     body/tail",
"    </span>",
"    tumors (n = 63). Compared to the all 5-FU treatment, the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    group had similar rates of nonhematologic grade 3 or 4 toxicity and febrile neutropenia despite significantly more grade 4 hematologic toxicity (14 versus 1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chemotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three randomized controlled clinical trials and two meta-analyses suggest a significant disease-free or overall survival benefit from chemotherapy alone without RT following resection of a pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/3,19,20,40-42\">",
"     3,19,20,40-42",
"    </a>",
"    ]. In the meta-analysis, the magnitude of benefit from chemotherapy alone was greater in patients with negative resection margins than in those with involved margins [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/42\">",
"     42",
"    </a>",
"    ]. This approach is commonly used outside of the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     5-FU based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite its methodologic problems, the results of the ESPAC-1 trial, discussed above, demonstrated a survival benefit from six months of postoperative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU in patients with resected pancreatic cancer, compared to those receiving no adjuvant chemotherapy (median overall survival 19.7 versus 14 months, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/19,20,43\">",
"     19,20,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comparable results were noted in a Norwegian trial that randomly assigned 61 patients with curatively resected pancreatic cancer to six cycles of 5-FU,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    (FAM) or observation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/3\">",
"     3",
"    </a>",
"    ]. Like the ESPAC-1 trial, chemotherapy was associated with a significantly longer median survival (23 versus 11 months). However, long-term survival was similar at both three (30 versus 27 percent) and five years (8 versus 4 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    was evaluated in the multinational European CONKO trial of 368 patients with grossly complete (R0 or R1) surgical resection and a preoperative CA 19-9 level &lt;2.5 times the upper limit of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/40\">",
"     40",
"    </a>",
"    ]. The patients were randomly assigned to gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1, 8, and 15 every four weeks for six months) or no treatment after surgery. Patients were stratified by resection margins (which were positive in about 17 percent of patients) and tumor (T) and nodal (N) status; the primary end point was disease-free survival (DFS).",
"   </p>",
"   <p>",
"    Adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    was associated with a significantly longer median DFS (13.4 versus 6.9 months), which was evident in those with negative (24.8 versus 10.4 months) and positive nodes (12.1 versus 6.4 months), as well as those with negative (13.1 versus 7.3 months) or positive margins (15.8 versus 5.5 months). In the most recent update, presented at the 2008 ASCO meeting, there was also a modest but significant improvement overall survival that favored gemcitabine (median 22.8 versus 20.2 months, p = 0.005, five-year survival 21 versus 9 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pattern of recurrence did not differ between the two groups. Local recurrence was a component of failure in 34 and 41 percent of the relapsing patients in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and observation groups, respectively. These data suggest that gemcitabine delayed rather than prevented the development of recurrent disease after resection of pancreatic cancer.",
"   </p>",
"   <p>",
"    A similar conclusion was reached in a smaller phase III Japanese trial of surgery alone or followed by a shorter duration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1, 8, and 15 for three months only) in 119 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/45\">",
"     45",
"    </a>",
"    ]. Although there was a significant improvement in DFS that favored gemcitabine (median 11.4 versus 5 months), the difference in survival (22 versus 18 months) was not significant, and the recurrence patterns were similar in both groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Gemcitabine versus a fluoropyrimidine",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1309507531\">",
"    <span class=\"h4\">",
"     ESPAC-3 trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;The multicenter ESPAC-3 trial randomly assigned 1088 patients with resected exocrine pancreatic cancer to six months of postoperative adjuvant treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for three of every four weeks) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    modulated 5-FU (leucovorin 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    followed by 5-FU 425",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV bolus days 1 through 5, every 28 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/46\">",
"     46",
"    </a>",
"    ]. At a median follow-up of 34 months, median survival was similar (23.6 versus 23 months with gemcitabine and fluoropyrimidine therapy, respectively). However, the patients assigned to",
"    <span class=\"nowrap\">",
"     5-FU/leucovorin",
"    </span>",
"    had more grade 3 to 4 treatment-related toxicity including stomatitis (10 versus 0 percent), diarrhea (13 versus 2 percent), and more treatment-related hospitalizations. Otherwise, progression-free survival and global quality of life scores were similar between the two groups.",
"   </p>",
"   <p>",
"    Given this safety profile,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    is the preferred agent when compared with monthly bolus (Mayo Clinic)",
"    <span class=\"nowrap\">",
"     5-FU/LV.",
"    </span>",
"    Whether similar efficacy results and a more tolerable safety profile are possible with a weekly or infusional fluoropyrimidine schedule are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1309507546\">",
"    <span class=\"h4\">",
"     Gemcitabine versus S-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;S-1 is an oral fluoropyrimidine that includes three different agents: ftorafur, chlorohydroxy dihydropyridine (a potent inhibitor of DPD [dihydropyrimidine dehydrogenase]), and oxonic acid (which inhibits phosphorylation of intestinal 5-FU, thought responsible for treatment-related diarrhea). It is approved in Japan for adjuvant treatment of gastric cancer and in Europe for treatment of advanced gastric cancer; it is not available in the United States.",
"   </p>",
"   <p>",
"    S-1 (40 to 60 mg twice daily for four weeks and repeated every six weeks for four courses) was directly compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 8, and 15 and repeated every four weeks for six courses) trial of 378 Japanese patients with resected pancreatic cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/47\">",
"     47",
"    </a>",
"    ]. In a preliminary report presented at the 2013 ASCO Gastrointestinal Cancers Symposium, S-1 was not inferior to gemcitabine (hazard ratio for death [HR] 0.56, 95% CI 0.42-0.74), and the two-year survival rates were 70 versus 53 percent. Although both treatments were associated with similarly low rates of grade 3 or 4 anorexia, thrombocytopenia, and anemia, gemcitabine was associated with more leukopenia (39 versus 9 percent) and transaminitis (5 versus 1 percent).",
"   </p>",
"   <p>",
"    Where available, S-1 represents a reasonable and more convenient alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    when adjuvant chemotherapy alone is recommended following resection of a pancreatic cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H698255022\">",
"    <span class=\"h3\">",
"     Chemotherapy versus chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Besides the ESPAC-1 trial, discussed above, the only other trial to compare the relative benefits of chemoradiotherapy versus systemic therapy alone was the EORTC",
"    <span class=\"nowrap\">",
"     40013/FFCD-9203/GERCOR",
"    </span>",
"    phase II study [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/9\">",
"     9",
"    </a>",
"    ]. Ninety patients with resected pancreatic cancer (70 percent node-positive, 97 percent completely resected [R0]) were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -based chemoradiotherapy (two cycles of weekly gemcitabine alone [1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly, three weeks on, one week off]) followed by RT (50.4 Gy in 28 daily 1.8 Gy fractions) with concurrent gemcitabine (300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once weekly four hours before RT for five to six weeks), or a control group. Initially the control group was observation alone (n = 4), but the protocol was amended, and the remainder of the control group (n = 41) received four cycles of gemcitabine alone (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for three consecutive weeks followed by a one week rest). Treatment started within eight weeks of surgery.",
"   </p>",
"   <p>",
"    In contrast to the results of the ESPAC-1 analysis, chemoradiotherapy was not deleterious; median DFS was 12 versus 11 months in the control group, and median overall survival was 24 months in both arms. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'ESPAC-1 trial'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Radiation therapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data address the benefit of adjuvant EBRT alone after potentially curative surgery. Following the publication of an early trial demonstrating a survival benefit for the addition of chemotherapy to RT compared to RT alone for locally advanced tumors of the GI tract [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/15\">",
"     15",
"    </a>",
"    ], chemoradiotherapy rather than RT alone has generally been the norm. None of the randomized trials described above addressed the benefit of RT in addition to chemotherapy.",
"   </p>",
"   <p>",
"    Some but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/48\">",
"     48",
"    </a>",
"    ] studies suggest that the use of intraoperative RT (IORT) in conjunction with surgical resection might improve survival [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/49-55\">",
"     49-55",
"    </a>",
"    ]. IORT permits the delivery of high-dose RT directly to areas at highest risk of local recurrence, while minimizing toxicity to adjacent normal tissues. Most trials have combined IORT with preoperative EBRT and chemotherapy (see below); none are randomized with a control group of resection without IORT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding the optimal management of patients following resection of pancreatic cancer, and the approach is different in Europe and in the United States.",
"   </p>",
"   <p>",
"    The European approach emphasizes the weaknesses of the early GITSG study and the lack of data demonstrating a significant survival benefit with chemoradiotherapy in the EORTC and ESPAC-1 trials. Most European clinicians support the conclusions of the ESPAC-1 trial (ie, that chemotherapy prolongs survival and chemoradiotherapy may actually worsen survival). The benefit of adjuvant chemotherapy alone is further supported by the German CONKO trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/40\">",
"     40",
"    </a>",
"    ]. Guidelines for treatment of pancreatic adenocarcinoma from the European Society of Medical Oncology suggest that chemoradiotherapy in the adjuvant setting should only be performed within the context of a randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/56\">",
"     56",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The American approach to adjuvant therapy differs with regard to the benefit of chemoradiotherapy and emphasizes the following points:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The high risk of local failure and potential for benefit from chemoradiotherapy",
"     </li>",
"     <li>",
"      The high rate of positive retroperitoneal margins and the impact of this finding on survival",
"     </li>",
"     <li>",
"      The survival benefit from chemoradiotherapy in the GITSG study",
"     </li>",
"     <li>",
"      The trend toward improved survival seen with chemoradiotherapy in the underpowered EORTC study",
"     </li>",
"     <li>",
"      The serious design flaws of the ESPAC-1 trial and the inherent difficulty in drawing definitive conclusions from this study",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the opinion of the authors (and the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf\">",
"     National Comprehensive Cancer Network [NCCN])",
"    </a>",
"    , patients who have undergone resection of an exocrine pancreatic cancer should be encouraged to enroll in clinical trials evaluating the potential benefits of chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemoradiotherapy as well as new therapies. As an example, RTOG trial 0848 is a phase III trial examining the benefit of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    to adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    with or without subsequent fluoropyrimidine-based chemoradiotherapy in patients with resected tumors of the head of the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Off protocol,",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    guidelines suggest 5-FU-based chemoradiotherapy plus systemic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    or chemotherapy alone (5-FU or gemcitabine). Given the results of the European ESPAC-3 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/58\">",
"     58",
"    </a>",
"    ], the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     NCCN",
"    </a>",
"    panel suggests gemcitabine rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU during the adjuvant chemotherapy component of therapy following resection of an exocrine pancreatic cancer. The early results from RTOG 9704 combined with the results from the CONKO trial provide support for adding gemcitabine adjuvant chemotherapy to chemoradiotherapy, at least for patients with pancreatic head tumors. The benefit of this approach is unproven for",
"    <span class=\"nowrap\">",
"     body/tail",
"    </span>",
"    lesions, but we tend to treat these patients similarly.",
"   </p>",
"   <p>",
"    The optimal way to sequence 5-FU-based chemoradiotherapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone is unclear. An acceptable regimen is that used in RTOG 9704, which consists of three weekly doses of gemcitabine alone (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per week), followed by chemoradiotherapy with concurrent infusional 5-FU [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/38\">",
"     38",
"    </a>",
"    ]. Although the RTOG trial used 5-FU 250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily, many clinicians find this dose excessively toxic and instead use 225",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily, five days per week. Following chemoradiation and starting three to five weeks later, patients receive three months of single agent gemcitabine (",
"    <a class=\"graphic graphic_table graphicRef81436 \" href=\"UTD.htm?26/2/26669\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32417?source=see_link\">",
"     \"Treatment protocols for pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, based upon logistical concerns as well as postoperative morbidity, clinicians may sequence chemoradiotherapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    differently than in the RTOG study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25683110\">",
"    <span class=\"h3\">",
"     Chemotherapy dosing in obese patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;For cancer patients with a large body surface area (BSA), chemotherapy drug doses are often reduced, because of concern for excess toxicity. However, there is no evidence that fully-dosed obese patients experience greater toxicity from chemotherapy for pancreatic cancer. Guidelines from ASCO recommend that full weight-based cytotoxic chemotherapy doses be used to treat obese patients with cancer, particularly when the goal of treatment is cure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     NEOADJUVANT THERAPY FOR POTENTIALLY RESECTABLE TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The low rate of resectability and the poor long-term outcomes following pancreaticoduodenectomy have led to the investigation of preoperative chemoradiotherapy or a combination of preoperative and postoperative therapies. The rationale for neoadjuvant approaches includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Improve the selection of patients for whom resection will not offer a survival benefit (ie, those who rapidly progress to metastatic disease during preoperative therapy)",
"     </li>",
"     <li>",
"      Increase rates of margin-negative resections",
"     </li>",
"     <li>",
"      Early treatment of micrometastatic disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections will review the efficacy of these approaches in patients with operable (potentially resectable) disease. Neoadjuvant approaches for patients with locally advanced (ie, unresectable or borderline resectable) disease are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33370?source=see_link\">",
"     \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     5 FU-based therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although initial reports of preoperative radiation therapy (RT) with or without concurrent 5-FU demonstrated that this approach did not worsen perioperative morbidity and mortality, there was no obvious improvement in either resectability or overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/60-64\">",
"     60-64",
"    </a>",
"    ]. A possible limitation of these initial studies is that most used single agent 5-FU. Subsequent studies have focused upon improving the treatment regimen by increasing the RT dose, adding intraoperative RT (IORT), and optimizing the chemotherapy regimen. These newer approaches appear to be tolerable, with low rates of hepatic toxicity and biliary stent-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/65-71\">",
"     65-71",
"    </a>",
"    ]. However, their efficacy remains uncertain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one series, 53 patients with potentially resectable pancreatic cancer received preoperative external beam RT (EBRT, 50.4 Gy), concurrent with infusional 5-FU (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day on days 2 through 5 and 29 through 32) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 2), and then followed by surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/66\">",
"       66",
"      </a>",
"      ]. Complete resection was possible in only 24 of the 41 patients who were explored. The median survival for the entire group and for the 24 resected patients was 10 and 16 months, respectively. One reason for these disappointing results was that many patients who underwent resection had advanced disease as evidenced by positive peritoneal cytology (which is considered M1 [stage IV] disease in the AJCC staging classification, (",
"      <a class=\"graphic graphic_table graphicRef62155 \" href=\"UTD.htm?42/32/43532\">",
"       table 1",
"      </a>",
"      )) (n = 3), close surgical margins (n = 13), involved nodes (n = 4), and the need for resection of the superior mesenteric vein (n = 4).",
"     </li>",
"     <li>",
"      A different approach combining preoperative chemoradiotherapy with resection and IORT was pursued by investigators at M D Anderson [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/67\">",
"       67",
"      </a>",
"      ]. Preoperative EBRT was administered to 39 patients by either conventional (50.4 Gy in 1.8 Gy fractions) or rapid fractionation (30 Gy in 3.0 Gy fractions) concurrent with chemotherapy and followed by IORT. Local control was achieved in 79 percent; 19 percent of patients were still alive at four years, and the median survival was 19 months. However, this regimen was associated with toxic gastrointestinal effects that required hospitalization in one-third of patients.",
"     </li>",
"     <li>",
"      These same investigators modified the treatment regimen to lessen gastrointestinal toxicity, and a further 35 patients were studied [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/68\">",
"       68",
"      </a>",
"      ]. Preoperative RT was administered over two weeks (30 Gy in 3.0 Gy daily fractions) concurrent with infusional 5-FU (300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day, five days per week) and followed by resection plus IORT (10 to 15 Gy). Of the 27 patients who underwent exploration, 20 were resected completely, and locoregional recurrence occurred in only 2 of 20. The median survival for the 20 resected patients was 25 months, and 23 percent were still alive at three years.",
"     </li>",
"     <li>",
"      A French study of 61 patients exploring the addition of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and 5-FU to preoperative RT demonstrated a major pathologic response in nine patients (three complete) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/70\">",
"       70",
"      </a>",
"      ]. Median survival for the 40 successfully resected patients was 11.7 months.",
"     </li>",
"     <li>",
"      However, less favorable results (median survival 9.4 months) using a slightly different regimen (higher doses of both chemotherapy and RT) were noted in a second French study of 41 patients with potentially resectable disease [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Substituting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      for 5-FU increased the toxicity of the neoadjuvant chemoradiotherapy regimen without improving the histologic response rate or survival [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Gemcitabine-based chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    -based chemoradiotherapy may provide an enhanced local effect, although with the potential for more toxicity than 5-FU-based regimens. Several early reports are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 86 patients with potentially resectable disease received seven weekly doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      (400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      plus concurrent RT (30 Gy in ten fractions over two weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/73\">",
"       73",
"      </a>",
"      ]. Hospitalization was required by almost one-half of patients during preoperative therapy. There was histologic complete response. Postoperatively, major complications developed in six patients (9 percent). The median survival for all patients was 22.7 months; it was 34 months among those who underwent pancreaticoduodenectomy and 7.1 months for those who did not. The five-year survival rate among resected patients was 36 percent.",
"     </li>",
"     <li>",
"      These same investigators explored the benefit of adding eight weeks of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      prior to a similar regimen of chemoradiotherapy (30 Gy EBRT over two weeks concurrent with four weekly courses of gemcitabine 400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      in 90 patients with clinical stage",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      adenocarcinoma of the pancreatic head or uncinate process [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/74\">",
"       74",
"      </a>",
"      ]. Hospitalization was required by more than one-half of all patients during preoperative therapy. Pancreaticoduodenectomy was accomplished in 52 patients, none of whom had a complete pathologic response; five (9.6 percent) experienced major perioperative complications. Median survival for the entire group was 17.4 months; it was 31 versus 10.5 months for the patients who did versus did not undergo pancreaticoduodenectomy, respectively.",
"     </li>",
"     <li>",
"      Others have studied preoperative full-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      and concurrent RT, modifying the RT field to minimize treatment-related toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/75\">",
"       75",
"      </a>",
"      ]. In a multi-institutional study, 20 patients with potentially resectable pancreatic cancer received two 21-day cycles of gemcitabine 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1 and 8, one administered before and one following a 28-day course of gemcitabine-based chemoradiotherapy (three-dimensional conformal RT 36 Gy in 15 fractions over 19 days concurrent with gemcitabine 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 8, and 15). RT was administered to the gross tumor target volume with 1 cm margins and did not include elective nodal irradiation. Nineteen patients completed therapy without interruption, and there was one grade 3 gastrointestinal toxicity. Seventeen patients underwent resection, 16 complete, and there was one pathologic complete response. With a median follow-up of 18 months, the median and two-year survival rates were 26 months and 61 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neoadjuvant chemotherapy alone without RT is beginning to be studied, but experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8234591\">",
"    <span class=\"h2\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least three meta-analyses have addressed the benefit of neoadjuvant therapy in patients with initially potentially resectable pancreatic cancer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 14 phase II trials concluded that among patients with potentially resectable pancreatic cancer, the rate of potentially curative resection after neoadjuvant therapy was 66 percent and median survival in the resected patients was 23 months [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second meta-analysis of seven prospective but uncontrolled trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -based neoadjuvant therapy in this setting concluded that 89 percent of initially resectable patients were able to undergo potentially curative resection, with a median survival in the resected patients of 31 months [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third analysis of 111 studies, including 56 phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trials, with 96 percent of the patients receiving chemotherapy and 94 percent RT, concluded that among patients with initially resectable disease, 35 percent had an objective response to neoadjuvant therapy while 21 percent had progressive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/80\">",
"       80",
"      </a>",
"      ]. Resectability rates were 74 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, whether these results represent an improvement in outcomes in patients who undergo resection without neoadjuvant therapy is unclear, given the lack of a surgery alone control arm in any of the trials included in any of the analyses. Thus, at present this cannot be considered a standard approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Adjuvant versus neoadjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While median survival durations from some uncontrolled trials reported of neoadjuvant therapy compare favorably to those reported with modern adjuvant therapy approaches [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/73,75,81\">",
"     73,75,81",
"    </a>",
"    ], whether preoperative therapy is better than postoperative therapy is uncertain. There are no randomized trials comparing the two approaches. One advantage of preoperative therapy is that it avoids the morbidity of pancreaticoduodenectomy in patients who have occult, micrometastatic disease that becomes clinically evident during therapy. A second advantage in patients undergoing pancreaticoduodenectomy is that prolonged recovery prevents the delivery of postoperative adjuvant chemotherapy in about one-fourth of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/82\">",
"     82",
"    </a>",
"    ]. This can be avoided with the neoadjuvant approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neoadjuvant chemoradiotherapy can be safely delivered to patients with localized pancreatic cancer without adversely influencing perioperative morbidity or mortality. However, no study has clearly demonstrated improved resectability or survival compared to patients treated with surgery alone, and it remains unclear whether this approach provides benefit compared to adjuvant (postoperative) therapy. The first US national trial of neoadjuvant therapy for potentially resectable pancreatic cancer (ACOSOG Z5041) is open, and eligible patients should be encouraged to enroll [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence to guide the posttreatment surveillance strategy in patients with pancreatic cancer, and clinical practice is variable, particularly with regard to CT scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/84\">",
"     84",
"    </a>",
"    ]. The primary goal of surveillance after curative treatment for any cancer is to detect local or distant recurrence when available interventions can prolong survival. For pancreatic cancer, most recurrences are not amenable to potentially curative therapy, and there is little evidence that early identification of recurrent or metastatic disease in asymptomatic patients improves long-term survival.",
"   </p>",
"   <p>",
"    Secondary benefits for early detection of metastatic disease include early introduction of palliative chemotherapy or radiation therapy to slow disease progression and (for patients who can tolerate an aggressive regimen such as FOLFIRINOX) improve survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39114?source=see_link&amp;anchor=H84834598#H84834598\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\", section on 'FOLFIRINOX'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The American Society of Clinical Oncology does not provide formal recommendations regarding posttreatment surveillance for pancreatic cancer. Consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    recommend a history and physical examination for symptom assessment every three to six months for two years, then annually with low level of evidence but uniform consensus. They suggest the use of CA 19-9 determinations and follow-up CT scans every three to six months for two years after surgical resection, then annually on the basis of low level evidence with nonuniform consensus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/21/11602?source=see_link\">",
"       \"Patient information: Pancreatic cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/55/31603?source=see_link\">",
"       \"Patient information: Pancreatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cancer of the exocrine pancreas is associated with a poor prognosis, even if a complete (R0) resection can be accomplished. Systemic chemotherapy, radiation therapy (RT), and a combination of chemotherapy and RT have all been applied following surgery in an effort to improve cure rates. Although the benefit of adjuvant therapy has become clearer in recent years, the optimal choice of treatment modality (chemotherapy with or without RT) remains intensely controversial. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no consensus regarding the optimal management of patients after resection of an exocrine pancreatic cancer, and the approach is different in Europe and in the United States:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Largely based upon the ESPAC-1 trial, which showed that 5-FU-containing chemotherapy prolongs survival, and results of the German CONKO trial showing a survival benefit from adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/40\">",
"       40",
"      </a>",
"      ], most European clinicians use chemotherapy alone after resection of a pancreatic neoplasm. Where available, oral therapy with S-1 represents an appropriate alternative to gemcitabine monotherapy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Chemotherapy alone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The American approach more often includes chemoradiotherapy as well as adjuvant chemotherapy. Guidelines from the",
"      <a class=\"external\" href=\"https://subscriptions.nccn.org/gl_login.aspx?ReturnURL=file://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf\">",
"       National Comprehensive Cancer Network",
"      </a>",
"      support either approach. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Chemoradiotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following represents our approach to patients with resected pancreatic tumors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eligible patients should be encouraged to enroll in clinical trials evaluating the potential benefits of chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemoradiotherapy as well as new therapies.",
"     </li>",
"     <li>",
"      Off-protocol, we suggest a combination of concurrent chemoradiotherapy and chemotherapy for all patients with resected pancreatic cancer (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). During the concurrent chemoradiotherapy portion, we prefer infusional 5-FU, and we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      alone for the chemotherapy portion. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Chemoradiotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Gemcitabine-based approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The optimal way to sequence 5-FU-based chemoradiotherapy and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      chemotherapy is unclear. An acceptable regimen is that used in RTOG 9704 [",
"      <a class=\"abstract\" href=\"UTD.htm?21/33/22042/abstract/38\">",
"       38",
"      </a>",
"      ], which consists of three weekly doses of gemcitabine alone (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week), followed by chemoradiotherapy using concurrent infusional 5-FU. Although the RTOG trial used 250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily continuously, many clinicians, including our group, consider this too toxic and use 225",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily, five days per week. Following chemoradiotherapy and starting three to five weeks later, three months of single agent gemcitabine (",
"      <a class=\"graphic graphic_table graphicRef81436 \" href=\"UTD.htm?26/2/26669\">",
"       table 2",
"      </a>",
"      ) are given. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Gemcitabine-based approaches'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32417?source=see_link\">",
"       \"Treatment protocols for pancreatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Although neoadjuvant chemoradiotherapy can be safely delivered to patients with localized pancreatic cancer, no study has clearly demonstrated improved resectability or survival, and it remains unclear whether this approach provides comparable benefit to adjuvant (postoperative) therapy. We suggest not administering neoadjuvant chemoradiotherapy outside of clinical trials at present (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Eligible patients should be encouraged to enroll on clinical trials testing this strategy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Neoadjuvant therapy for potentially resectable tumors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/2\">",
"      Trede M, Schwall G, Saeger HD. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality. Ann Surg 1990; 211:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/3\">",
"      Bakkevold KE, Arnesj&oslash; B, Dahl O, Kambestad B. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater--results of a controlled, prospective, randomised multicentre study. Eur J Cancer 1993; 29A:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/4\">",
"      Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/5\">",
"      Tsao JI, Rossi RL, Lowell JA. Pylorus-preserving pancreatoduodenectomy. Is it an adequate cancer operation. Arch Surg 1994; 129:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/6\">",
"      Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995; 221:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/7\">",
"      Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/8\">",
"      Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27:1806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/9\">",
"      Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010; 28:4450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/10\">",
"      Willett CG, Lewandrowski K, Warshaw AL, et al. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Ann Surg 1993; 217:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/11\">",
"      Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/12\">",
"      Nishimura Y, Hosotani R, Shibamoto Y, et al. External and intraoperative radiotherapy for resectable and unresectable pancreatic cancer: analysis of survival rates and complications. Int J Radiat Oncol Biol Phys 1997; 39:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/13\">",
"      Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/14\">",
"      Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/15\">",
"      Moertel CG, Childs DS Jr, Reitemeier RJ, et al. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969; 2:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/16\">",
"      Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/17\">",
"      Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987; 59:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/18\">",
"      Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/19\">",
"      Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/20\">",
"      Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/21\">",
"      Hsu CC, Herman JM, Corsini MM, et al. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010; 17:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/22\">",
"      Hattangadi JA, Hong TS, Yeap BY, Mamon HJ. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Cancer 2009; 115:3640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/23\">",
"      Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am J Surg 1991; 161:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/24\">",
"      Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/25\">",
"      Whittington R, Bryer MP, Haller DG, et al. Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 1991; 21:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/26\">",
"      Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/27\">",
"      Vanderveen KA, Chen SL, Yin D, et al. Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis. Cancer 2009; 115:2420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/28\">",
"      Abrams RA, Grochow LB, Chakravarthy A, et al. Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. Int J Radiat Oncol Biol Phys 1999; 44:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/29\">",
"      Carr JA, Ajlouni M, Wollner I, et al. Adenocarcinoma of the head of the pancreas: effects of surgical and nonsurgical therapy on survival--a ten-year experience. Am Surg 1999; 65:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/30\">",
"      Mehta VK, Fisher GA, Ford JM, et al. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 2000; 48:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/31\">",
"      McDade TP, Hill JS, Simons JP, et al. A national propensity-adjusted analysis of adjuvant radiotherapy in the treatment of resected pancreatic adenocarcinoma. Cancer 2010; 116:3257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/32\">",
"      Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003; 185:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/33\">",
"      Picozzi VJ, Abrams RA, Decker PA, et al. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031. Ann Oncol 2011; 22:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/34\">",
"      Schmidt J, Abel U, Debus J, et al. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma. J Clin Oncol 2012; 30:4077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/35\">",
"      Demols A, Peeters M, Polus M, et al. Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study. Int J Radiat Oncol Biol Phys 2005; 62:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/36\">",
"      Wilkowski R, Thoma M, D&uuml;hmke E, et al. Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 2004; 58:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/37\">",
"      Blackstock AW, Mornex F, Partensky C, et al. Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study. Br J Cancer 2006; 95:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/38\">",
"      Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/39\">",
"      Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011; 18:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/40\">",
"      Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/41\">",
"      Stocken DD, B&uuml;chler MW, Dervenis C, et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92:1372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/42\">",
"      Butturini G, Stocken DD, Wente MN, et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008; 143:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/43\">",
"      Neoptolemos JP, Stocken DD, Tudur Smith C, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009; 100:246.",
"     </a>",
"    </li>",
"    <li>",
"     Neuhaus P, Riess H, Post S, et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine vs. observation in patients with resected pancreatic cancer (abstract). J Clin Oncol 2008; 26:1009s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/45\">",
"      Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/46\">",
"      Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304:1073.",
"     </a>",
"    </li>",
"    <li>",
"     Uesaka K, Fukutomi A,  Boku N, et al. Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer (JASPAC-01 study) (abstract). J Clin Oncol 30: 2012 (suppl 34; abstr 145). file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=133&amp;abstractID=105691 (Accessed on February 08, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/48\">",
"      Showalter TN, Rao AS, Rani Anne P, et al. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis. Ann Surg Oncol 2009; 16:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/49\">",
"      Sindelar WF, Kinsella TJ. Studies of intraoperative radiotherapy in carcinoma of the pancreas. Ann Oncol 1999; 10 Suppl 4:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/50\">",
"      Hishinuma S, Ogata Y, Matsui J, Ozawa I. Results of surgery and adjuvant radiotherapy for pancreatic cancer. J Hepatobiliary Pancreat Surg 1998; 5:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/51\">",
"      Hosotani R, Kogire M, Arii S, et al. Results of pancreatectomy with radiation therapy for pancreatic cancer. Hepatogastroenterology 1997; 44:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/52\">",
"      Dobelbower RR, Merrick HW, Khuder S, et al. Adjuvant radiation therapy for pancreatic cancer: a 15-year experience. Int J Radiat Oncol Biol Phys 1997; 39:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/53\">",
"      Farrell TJ, Barbot DJ, Rosato FE. Pancreatic resection combined with intraoperative radiation therapy for pancreatic cancer. Ann Surg 1997; 226:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/54\">",
"      Tuckson WB, Goldson AL, Ashayeri E, et al. Intraoperative radiotherapy for patients with carcinoma of the pancreas. The Howard University Hospital experience, 1978-1986. Ann Surg 1988; 207:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/55\">",
"      Hiraoka T, Uchino R, Kanemitsu K, et al. Combination of intraoperative radiation with resection of cancer of the pancreas. Int J Pancreatol 1990; 7:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/56\">",
"      Seufferlein T, Bachet JB, Van Cutsem E, et al. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 Suppl 7:vii33.",
"     </a>",
"    </li>",
"    <li>",
"     Information on RTOG trial 0848 available online at file://clinicaltrials.gov/ct2/show/NCT01013649?term=RTOG+0848&amp;rank=1 (Accessed on February 03, 2011).",
"    </li>",
"    <li>",
"     Neoptolemos J, Buchler M, Stocken DD, et al. ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine in patients with resectedpancreatic ductal adenocarcinoma (abstract #LBA4505). J Clin Oncol 2009; 27:797s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/59\">",
"      Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2012; 30:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/60\">",
"      Pilepich MV, Miller HH. Preoperative irradiation in carcinoma of the pancreas. Cancer 1980; 46:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/61\">",
"      Kopelson G. Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre or postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1983; 9:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/62\">",
"      Ishikawa O, Ohhigashi H, Teshima T, et al. Clinical and histopathological appraisal of preoperative irradiation for adenocarcinoma of the pancreatoduodenal region. J Surg Oncol 1989; 40:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/63\">",
"      Jessup JM, Steele G Jr, Mayer RJ, et al. Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 1993; 128:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/64\">",
"      Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/65\">",
"      Pisters PW, Hudec WA, Lee JE, et al. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. J Clin Oncol 2000; 18:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/66\">",
"      Hoffman JP, Lipsitz S, Pisansky T, et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998; 16:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/67\">",
"      Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am J Surg 1996; 171:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/68\">",
"      Pisters PW, Abbruzzese JL, Janjan NA, et al. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. J Clin Oncol 1998; 16:3843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/69\">",
"      Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol 2002; 20:2537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/70\">",
"      Moutardier V, Magnin V, Turrini O, et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2004; 60:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/71\">",
"      White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001; 8:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/72\">",
"      Le Scodan R, Mornex F, Girard N, et al. Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. Ann Oncol 2009; 20:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/73\">",
"      Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26:3496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/74\">",
"      Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26:3487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/75\">",
"      Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006; 13:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/76\">",
"      Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007; 14:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/77\">",
"      Heinrich S, Pestalozzi BC, Sch&auml;fer M, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol 2008; 26:2526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/78\">",
"      Assifi MM, Lu X, Eibl G, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 2011; 150:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/79\">",
"      Andriulli A, Festa V, Botteri E, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 2012; 19:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/80\">",
"      Gillen S, Schuster T, Meyer Zum B&uuml;schenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7:e1000267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/81\">",
"      Meszoely IM, Wang H, Hoffman JP. Preoperative chemoradiation therapy for adenocarcinoma of the pancreas: The Fox Chase Cancer Center experience, 1986-2003. Surg Oncol Clin N Am 2004; 13:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/82\">",
"      Spitz FR, Abbruzzese JL, Lee JE, et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol 1997; 15:928.",
"     </a>",
"    </li>",
"    <li>",
"     Information on the ACOSOG Z5041 trial can be obtained online at file://clinicaltrials.gov/ct2/results?term=ACOSOG+Z5041 (Accessed on December 14, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/33/22042/abstract/84\">",
"      Sheffield KM, Crowell KT, Lin YL, et al. Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol 2012; 19:1670.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2477 Version 26.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-3FB984B900-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22042=[""].join("\n");
var outline_f21_33_22042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ADJUVANT THERAPY FOR PANCREATIC CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - GITSG study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - EORTC study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - ESPAC-1 trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Uncontrolled series",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Interferon plus 5-FU and cisplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Gemcitabine-based approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chemotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - 5-FU based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Gemcitabine versus a fluoropyrimidine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1309507531\">",
"      ESPAC-3 trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1309507546\">",
"      Gemcitabine versus S-1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H698255022\">",
"      - Chemotherapy versus chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Radiation therapy alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25683110\">",
"      - Chemotherapy dosing in obese patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      NEOADJUVANT THERAPY FOR POTENTIALLY RESECTABLE TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      5 FU-based therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Gemcitabine-based chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8234591\">",
"      Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Adjuvant versus neoadjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2477\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2477|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/32/43532\" title=\"table 1\">",
"      TNM panc endo exo CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/2/26669\" title=\"table 2\">",
"      Gemcitabine for nonmetastatic pancreatic and biliary cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=related_link\">",
"      Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39114?source=related_link\">",
"      Chemotherapy for advanced exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/37/33370?source=related_link\">",
"      Management of locally advanced and borderline resectable exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/27/44472?source=related_link\">",
"      Pathology of exocrine pancreatic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/55/31603?source=related_link\">",
"      Patient information: Pancreatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/21/11602?source=related_link\">",
"      Patient information: Pancreatic cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=related_link\">",
"      Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32417?source=related_link\">",
"      Treatment protocols for pancreatic cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_33_22043="Risk devel BC white women";
var content_f21_33_22043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52691&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Average five-year and lifetime risk of developing breast cancer among white women, by age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Five-year risk, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lifetime (until age 90) risk, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        12.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        0.6",
"       </td>",
"       <td>",
"        12.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"       <td>",
"        11.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        1.8",
"       </td>",
"       <td>",
"        9.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        2.2",
"       </td>",
"       <td>",
"        6.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"       <td>",
"        3.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"       <td>",
"        1.4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Breast Cancer Risk Assessment Tool. National Institutes of Health. Available at: www.cancer.gov/bcrisktool.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22043=[""].join("\n");
var outline_f21_33_22043=null;
var title_f21_33_22044="Failure to respond to iron";
var content_f21_33_22044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F56310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F56310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes for failure to respond to oral iron therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Coexisting disease interfering with marrow response",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory disorder (eg, rheumatoid arthritis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Concomitant malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coexisting folic acid and/or vitamin B12 deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone marrow suppression from another cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Diagnosis is incorrect, possible correct diagnoses include",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thalassemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lead poisoning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anemia of chronic disease (anemia of chronic inflammation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copper deficiency (zinc toxicity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myelodysplastic syndrome/refractory sideroblastic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient is not taking the medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prescription has not been filled",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prescription has been filled but patient is no longer taking the medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medication is being taken but is not being absorbed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapid intestinal transport bypasses area of maximum absorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteric coated product: coating is not dissolving",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient has malabsorption for iron (eg, sprue, atrophic gastritis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medication taken in association with an agent interfering with absorption (eg, antacids, tetracycline, tea)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Continued blood loss or need in excess of iron dose ingested",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cause of blood loss treatable (eg, bleeding peptic ulcer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Initiate appropriate treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cause of blood loss not treatable (eg, Osler Weber Rendu disease) or need cannot be met by oral iron preparation (eg, renal failure responding to erythropoietin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Switch patient to parenteral iron product",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Assumes that original diagnosis was iron deficiency anemia with hypochromic microcytic red blood cells, low ferritin, and low tranferrin saturation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22044=[""].join("\n");
var outline_f21_33_22044=null;
var title_f21_33_22045="MTX ectopic preg protocol";
var content_f21_33_22045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56738&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Methotrexate treatment protocol for tubal or interstitial ectopic pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"3\">",
"       Pretreatment testing and instructions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       hCG concentration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Transvaginal ultrasound",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Blood group and Rh(D) typing; give anti Rh(D) immune globulin 300 mcg IM, if indicated",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Complete blood count",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Liver and renal function tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Discontinue folic acid supplements",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Counsel patient to avoid nonsteroidal antiinflammatory medications, recommend acetaminophen if an analgesic is needed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       Advise patient to refrain from sexual intercourse and strenuous exercise",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Treatment day",
"      </td>",
"      <td class=\"subtitle1\">",
"       Single dose protocol",
"      </td>",
"      <td class=\"subtitle1\">",
"       Multiple dose protocol",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"2\">",
"       1",
"      </td>",
"      <td>",
"       hCG concentration",
"      </td>",
"      <td>",
"       hCG concentration",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       MTX 50 mg/m2 body surface area IM",
"      </td>",
"      <td>",
"       MTX 1mg/kg bodyweight IM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       LEU 0.1 mg/kg PO",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"3\">",
"       3",
"      </td>",
"      <td rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       hCG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If &lt;15 percent hCG decline from day 1 to 3, give MTX 1 mg/kg IM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If &ge;15 percent decline from day 1 to 3, begin weekly hCG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4",
"      </td>",
"      <td>",
"       hCG (protocols vary, see day 7)",
"      </td>",
"      <td>",
"       LEU 0.1 mg/kg PO*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"3\">",
"       5",
"      </td>",
"      <td rowspan=\"3\">",
"       &nbsp;",
"      </td>",
"      <td>",
"       hCG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If &lt;15 percent decline from day 3 to 5 MTX, give MTX 1 mg/kg IM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If &ge;15 percent decline from day 3 to 5, begin weekly hCG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       6",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       LEU 0.1 mg/kg PO*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"3\">",
"       7",
"      </td>",
"      <td>",
"       hCG",
"      </td>",
"      <td>",
"       hCG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If &lt;15 percent hCG decline from day 4 to 7 (OR &lt;25 percent decline from day 1 to 7), give additional dose of MTX 50 mg/m2 IM",
"      </td>",
"      <td>",
"       If &lt;15 percent decline from day 5 to 7 MTX, give MTX 1 mg/kg IM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If &ge;15 percent hCG decline from day 4 to 7 (OR &ge;25 percent decline from day 1 to 7), draw hCG concentration weekly until hCG is undetectable",
"      </td>",
"      <td>",
"       If &ge;15 percent decline from day 5 to 7, begin weekly hCG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       8",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       LEU 0.1 mg/kg PO*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" rowspan=\"3\">",
"       14",
"      </td>",
"      <td>",
"       hCG",
"      </td>",
"      <td>",
"       hCG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If &lt;15 percent hCG decline from day 7 to 14, give additional dose of MTX 50 mg/m2 IM",
"      </td>",
"      <td>",
"       If &lt;15 percent hCG decline from day 7 to 14, give additional dose of MTX 1 mg/kg IM (give LEU 0.1 mg/kg PO on day 15)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       If &ge;15 percent hCG decline from day 7 to 14, check hCG weekly until undetectable",
"      </td>",
"      <td>",
"       If &ge;15 percent hCG decline from day 7 to 14, check hCG weekly until undetectable",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       21 and 28",
"      </td>",
"      <td>",
"       If 3 doses have been given and there is a &lt;15 percent hCG decline from day 21 to 28, proceed with laparocopic surgery",
"      </td>",
"      <td>",
"       If 5 doses have been given and there is a &lt;15 percent hCG decline from day 14 to 21, proceed with laparoscopic surgery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"3\">",
"       Laparoscopy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       If severe abdominal pain or an acute abdomen suggestive of tubal rupture occurs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\" colspan=\"3\">",
"       If ultrasonography reveals greater than 300 mL pelvic or other intraperitoneal fluid",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     hCG: human chorionic gonadotropin beta-subunit; MTX: methotrexate; IM: intramuscular; LEU: leucovorin; PO: oral route.",
"     <br>",
"      * Leucovorin is given only if methotrexate was given on the previous day.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22045=[""].join("\n");
var outline_f21_33_22045=null;
var title_f21_33_22046="Contents: Endocarditis and bacteremia";
var content_f21_33_22046=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?15/21/15710\">",
"       Infectious Diseases",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Endocarditis and bacteremia",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Endocarditis and bacteremia",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Bacteremia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/14/11494\">",
"           Blood cultures for the detection of bacteremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/1/26649\">",
"           Complications of Staphylococcus aureus bacteremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/1/10263\">",
"           Epidemiology of Staphylococcus aureus bacteremia in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/43/24249\">",
"           Treatment of Staphylococcus aureus bacteremia in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Infective endocarditis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/25/41367\">",
"           Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/36/585\">",
"           Antimicrobial prophylaxis for bacterial endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/37/20058\">",
"           Antimicrobial therapy of native valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/57/34712\">",
"           Antimicrobial therapy of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/39/40566\">",
"           Candida endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/52/18249\">",
"           Complications and outcome of infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/53/34646\">",
"           Culture-negative endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/24/41352\">",
"           Diagnostic approach to infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/5/31830\">",
"           Endocarditis caused by Bartonella",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/12/5317\">",
"           Endocarditis due to coagulase-negative staphylococci",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/40/2697\">",
"           Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/31/14840\">",
"           Epidemiology, risk factors and microbiology of infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/17/40215\">",
"           Infective endocarditis in injection drug users",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/23/31094\">",
"           Infective endocarditis: Historical and Duke criteria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/37/2648\">",
"           Nonarrhythmic complications of mitral valve prolapse",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/19/17718\">",
"           Pathogenesis of vegetation formation in infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/27/14775\">",
"           Pseudomonas aeruginosa bacteremia and endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/30/35303\">",
"           Purulent pericarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/57/15255\">",
"           Q fever endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/27/5556\">",
"           Renal disease in the setting of infective endocarditis or an infected ventriculoatrial shunt",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/8/20617\">",
"           Role of echocardiography in infective endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/49/22297\">",
"           Surgery for native valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/32/3591\">",
"           Surgery for prosthetic valve endocarditis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prosthetic device infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/36/585\">",
"           Antimicrobial prophylaxis for bacterial endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/57/34712\">",
"           Antimicrobial therapy of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/40/2697\">",
"           Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/19/44345\">",
"           Infections involving cardiac implantable electronic devices",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/32/3591\">",
"           Surgery for prosthetic valve endocarditis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Vascular infections",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/17/35098\">",
"           Overview of infected (mycotic) arterial aneurysm",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/41/6807\">",
"           Septic pelvic thrombophlebitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/0/2055\">",
"           Suppurative (septic) thrombophlebitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-42600B4DFA-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f21_33_22046=[""].join("\n");
var outline_f21_33_22046=null;
var title_f21_33_22047="Scheme thymic T cell development";
var content_f21_33_22047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76102&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 696px\">",
"   <div class=\"ttl\">",
"    Scheme of thymic T cell development in alpha-beta T cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 676px; height: 288px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of T cell development in the thymus. The various stages of maturation include the double negative (DN) stages (1, 2, 3, and 4), double positive (DP) stage, and single positive (SP) stage. The lower part of the figure indicates TCR2 rearrangements which correspond to each stage. The upper part of the figure demonstrates some of the receptors expressed at each stage of differentiation.",
"    <div class=\"footnotes\">",
"     TCR2: T cell receptor type 2 or T cell receptor alpha-beta.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_33_22047=[""].join("\n");
var outline_f21_33_22047=null;
